Abstract
The issue number is given in front of the pagination
Aalten, P., see Freeze, W.M. (1) 333–342
Aalten, P., see Jansen, W.J. (2) 679–689
Abdin, E., see Peh, C.X. (2) 823–833
Abrevaya, S., L. Sedeño, S. Fitipaldi, D. Pineda, F. Lopera, O. Buritica, A. Villegas, C. Bustamante, D. Gomez, N. Trujillo, R. Pautassi, A. Ibáñez and A.M. Garcíaa, The Road Less Traveled: Alternative Pathways for Action-Verb Processing in Parkinson’s Disease (4) 1429–1435
Acevedo, L.A., see Fisher, C.L. (1) 391–410
Adorni, M.P., see Zimetti, F., (1) 315–320
Ahn, S., see Kim, H.-R. (1) 137–146
Ai, L., see Chang, P. (1) 77–87
Alafuzoff, I., see Laiterä, T. (3) 995–1003
Alciato, F., see Sainaghi, P.P. (1) 59–65
Alcolea, D., see Carmona-Iragui, M. (4) 1489–1496
Alcolea, D., see Gamir-Morralla, A. (4) 1327–1333
Alexander, R.C., see Cebers, G. (3) 1039–1053
Allali, G., see Beauchet, O. (3) 965–971
Allan, S.M., see Martins, I.V.A. (3) 915–932
Alonso, J.F., see Ochoa, J.F. (3) 1195–1205
Altiner, A., see Teipel, S.J. (4) 1379–1394
Amano, N., see Okamoto, N. (2) 575–583
An, H., B. Choi, K.-w. Park, D.-H. Kim, D.-W. Yang, C.H. Hong, S.Y. Kim and S.-H. Han, The Effect of Escitalopram on Mood and Cognition in Depressive Alzheimer’s Disease Subjects (2) 727–735
Anbarjafari, G., see Beheshti, I. (4) 1571–1582
Andel, R., see Pařízková, M. (3) 951–964
Anderson, A., see McClure, R. (2) 797–811
Anderson, M., F. Xu, M.-H. Ou-Yang, J. Davis, W.E. Van Nostrand and J.K. Robinson, Intensive ‘Brain Training’ Intervention Fails to Reduce Amyloid Pathologies or Cognitive Deficits in Transgenic Mouse Models of Alzheimer’s Disease (3) 1109–1121
Andreotti, J., T. Dierks, L.-O. Wahlund and M. Grieder, Diverging Progression of Network Disruption and Atrophy in Alzheimer’s Disease and Semantic Dementia (3) 981–993
Anfossi, M., see Cupidi, C. (3) 1249–1259
Antoine, P., see Wawrziczny, E. (2) 703–716
Antonelli, F., see Buongiorno, M. (3) 1261–1272
Araque Caballero, M.Á., S. Klöppel, M. Dichgans, M. Ewers and for the Alzheimer’s Disease Neuroimaging Initiative, Spatial Patterns of Longitudinal Gray Matter Change as Predictors of Concurrent Cognitive Decline in Amyloid Positive Healthy Subjects (1) 343–358
Ardekani, B.A., E. Bermudez, A.M. Mubeen, A.H. Bachman and for the Alzheimer’s Disease Neuroimaging Initiative, Prediction of Incipient Alzheimer’s Disease Dementia in Patients with Mild Cognitive Impairment (1) 269–281
Argueta, J., see Coskun, P. (2) 737–748
Ariga, H., see Kitamura, Y. (1) 67–72
Arnerić, S.P., R. Batrla-Utermann, L. Beckett, T. Bittner, K. Blennow, L. Carter, R. Dean, S. Engelborghs, J. Genius, M.F. Gordon, J. Hitchcock, J. Kaplow, J. Luthman, R. Meibach, D. Raunig, K. Romero, M.N. Samtani, M. Savage, L. Shaw, D. Stephenson, R.M. Umek, H. Vanderstichele, B. Willis and S. Yule, Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team (1) 19–35
Arnold, S.E., see Quarmley, M. (4) 1497–1507
Arreche, S.C., see de la Rubia Ortí, J.E. (3) 899–903
Arroyo-Anlló, E.M., A.T. Bouston, M.-N. Fargeau, B.O. Baz and R. Gil, Self-Consciousness Deficits in Alzheimer’s Disease and Frontotemporal Dementia (4) 1437–1443
Ashihara, E., see Kitamura, Y. (1) 67–72
Assini, A.G., see Miranda, L.F.J.R. (2) 539–549
Asthana, S., see Darst, B.F. (2) 473–484
Azuma, S., see Kazui, H. (4) 1403–1416
Baarends, G., see Philippens, I.H. (1) 101–113
Bachman, A.H., see Ardekani, B.A. (1) 269–281
Backes, W.H., see Freeze, W.M. (1) 333–342
Baek, M.J., see Kim, H.-R. (1) 137–146
Bang, J., see Fong, J.C. (1) 249–258
Banks, W.A., A. Kovac, P. Majerova, K.M. Bullock, M. Shi and J. Zhang, Tau Proteins Cross the Blood-Brain Barrier (1) 411–419
Baran, T.M., see Lin, F., (2) 669–678
Barayuga, S.M., see Rueli, R.H.L.H. (2) 749–762
Bargalló, N., see Grau-Rivera, O. (1) 431–443
Barkhof, F., see Freeze, W.M. (1) 333–342
Barkhof, F., see Hafkemeijer, A. (2) 521–537
Barocco, F., see Zimetti, F., (1) 315–320
Barrio, J.R., see Buongiorno, M. (3) 1261–1272
Barton, S., see McClure, R. (2) 797–811
Barulli, M.R., see Papazacharias, A. (3) 973–979
Basora, M., see Buongiorno, M. (3) 1261–1272
Batrla-Utermann, R., see Arnerić, S.P. (1) 19–35
Bauer, C., see Prete, D.D. (4) 1549–1570
Baz, B.O., see Arroyo-Anlló, E.M. (4) 1437–1443
Bea Kuiperij, H., A.A.M. Versleijen, M. Beenes, N.A. Verwey, L. Benussi, A. Paterlini, G. Binetti, C.E. Teunissen, J. Raaphorst, H.J. Schelhaas, B. Küsters, Y.A.L. Pijnenburg, R. Ghidoni and M.M. Verbeek, Tau Rather than TDP-43 Proteins are Potential Cerebrospinal Fluid Biomarkers for Frontotemporal Lobar Degeneration Subtypes: A Pilot Study (2) 585–595
Beauchet, O., C.P. Launay, J. Chabot, E.J. Levinoff and G. Allali, Subjective Memory Impairment and Gait Variability in Cognitively Healthy Individuals: Results from a Cross-Sectional Pilot Study (3) 965–971
Becker, J.T., see Slachevsky, A. (4) 1595–1603
Beckett, L., see Arnerić, S.P. (1) 19–35
Beenes, M., see H. Bea Kuiperij, (2) 585–595
Beesley, S., J. Olcese, C. Saunders and E.A. Bienkiewicz, Combinatorial Treatment Effects in a Cell Culture Model of Alzheimer’s Disease (3) 1155–1166
Beheshti, I., N. Maikusa, H. Matsuda, H. Demirel, G. Anbarjafari and for the Japanese-Alzheimer’s Disease Neuroimaging Initiative, Histogram-Based Feature Extraction from Individual Gray Matter Similarity-Matrix for Alzheimer’s Disease Classification (4) 1571–1582
Belbin, O., see Gamir-Morralla, A. (4) 1327–1333
Bellan, M., see Sainaghi, P.P. (1) 59–65
Bellinger, F.P., see Rueli, R.H.L.H. (2) 749–762
Bellinger, M.T., see Rueli, R.H.L.H. (2) 749–762
Bendlin, B.B., see Darst, B.F. (2) 473–484
Benejam, B., see Carmona-Iragui, M. (4) 1489–1496
Benlloch, M., see de la Rubia Ortí, J.E. (3) 899–903
Bennett, D.A., see Cummings, J. (3) 1131–1139
Benussi, L., see H. Bea Kuiperij, (2) 585–595
Bergeron, D., A. Vermette, J. De La Sablonnière, A.-M. Cayer, R. Jr. Laforce and R.W. Bouchard, Finger-to-Nose Test Findings in Alzheimer’s Disease (4) 1335–1337
Bergman, P., see Håkansson, K. (2) 645–657
Bermudez, E., see Ardekani, B.A. (1) 269–281
Berna, G., see Wawrziczny, E. (2) 703–716
Bernardi, G., see Sancesario, G.M. (4) 1659–1666
Bernardi, L., see Cupidi, C. (3) 1249–1259
Bernini, F., see Zimetti, F., (1) 315–320
Berry, M.J., see Rueli, R.H.L.H. (2) 749–762
Bertolucci, P.H.F., see Cummings, J. (3) 1131–1139
Berumen, L.C., see Mendiola-Precoma, J. (3) 1273–1283
Bienkiewicz, E.A., see Beesley, S. (3) 1155–1166
Binetti, G., see H. Bea Kuiperij, (2) 585–595
Bischof, G.N., see Dronse, J. (2) 465–471
Bittner, T., see Arnerić, S.P. (1) 19–35
Blennow, K., see Arnerić, S.P. (1) 19–35
Blennow, K., see Carmona-Iragui, M. (4) 1489–1496
Blennow, K., see Darst, B.F. (2) 473–484
Blennow, K., see Idland, A.-V. (1) 371–379
Blennow, K., see Lewczuk, P. (1) 159–170
Blennow, K., see Lewczuk, P. (2) 813–822
Blennow, K., see Russell, C.L. (1) 303–313
Blesa, R., see Carmona-Iragui, M. (4) 1489–1496
Blesa, R., see Cummings, J. (3) 1131–1139
Boeve, B.F., see Savica, R. (2) 559–567
Bogdanovic, N., see Idland, A.-V. (1) 371–379
Bohannan, R.C., see Coskun, P. (2) 737–748
Bøhmer, T., see Ulstein, I. (2) 717–725
Bonnet, A.-L., see Duclos, H. (2) 459–463
Borghi, R., see Monacelli, F. (4) 1295–1306
Bos, D., see Wolters, F.J. (3) 893–897
Bouchard, R.W., see Bergeron, D. (4) 1335–1337
Bougea, A., see Paraskevas, G.P. (4) 1453–1461
Bourassa, P., see Dal-Pan, A. (1) 115–135
Bourdoulous, M., see Dal-Pan, A. (1) 115–135
Bouston, A.T., see Arroyo-Anlló, E.M. (4) 1437–1443
Bouwman, F., see Jansen, W.J. (2) 679–689
Bozzali, M., see Serra, L. (1) 421–430
Brækhus, A., see Idland, A.-V. (1) 371–379
Brandner, S., see Lewczuk, P. (1) 159–170
Bravo, E., see Slachevsky, A. (4) 1595–1603
Brem, A.-K., see Fried, P.J. (1) 89–100
Bruni, A.C., see Cupidi, C. (3) 1249–1259
Budamagunta, M., see Hilt, S. (4) 1667–1681
Bullock, K.M., see Banks, W.A. (1) 411–419
Buongiorno, M., F. Antonelli, Y. Compta, Y. Fernandez, J. Pavia, F. Lomeña, J. Ríos, I. Ramírez, J.R. García, M. Soler, A. Cámara, M. Fernández, M. Basora, F. Salazar, G. Sanchez-Etayo, F. Valldeoriola, J.R. Barrio and M.J. Marti, Cross-Sectional and Longitudinal Cognitive Correlates of FDDNP PET and CSF Amyloid-β and Tau in Parkinson’s Disease (3) 1261–1272
Burgmans, S., see Freeze, W.M. (1) 333–342
Buritica, O., see Abrevaya, S. (4) 1429–1435
Busciglio, J., see Coskun, P. (2) 737–748
Bussè, C., see Cagnin, A. (4) 1529–1536
Bussiere, R., see Prete, D.D. (4) 1549–1570
Bustamante, C., see Abrevaya, S. (4) 1429–1435
Butts, A.M., see Krishnan, K. (3) 1019–1029
Byrro, R.M.D., see Miranda, L.F.J.R. (2) 539–549
Byun, H.J., see Han, J.W. (2) 787–796
Caffarra, P., see Zimetti, F., (1) 315–320
Cagnin, A., F. Fragiacomo, G. Camporese, M. Turco, C. Bussè, M. Ermani and S. Montagnese, Sleep-Wake Profile in Dementia with Lewy Bodies, Alzheimer’s Disease, and Normal Aging (4) 1529–1536
Calon, F., see Dal-Pan, A. (1) 115–135
Calvo, A., see Grau-Rivera, O. (1) 431–443
Cámara, A., see Buongiorno, M. (3) 1261–1272
Camporese, G., see Cagnin, A. (4) 1529–1536
Cantello, R., see Sainaghi, P.P. (1) 59–65
Capellari, S., see Rumeileh, S.A. (4) 1471–1480
Capozzo, R., see Papazacharias, A. (3) 973–979
Cappa, S.F., see Cerami, C. (1) 183–197
Caramelli, P., see Miranda, L.F.J.R. (2) 539–549
Carecchio, M., see Sainaghi, P.P. (1) 59–65
Carita, P., see Leger, D. (1) 321–331
Carlsson, C.M., see Darst, B.F. (2) 473–484
Carlsson, R., see Håkansson, K. (2) 645–657
Carmona-Iragui, M., T. Santos, S. Videla, S. Fernández, B. Benejam, L. Videla, D. Alcolea, K. Blennow, R. Blesa, A. Lleo and J. Fortea, Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease in Subjects with Down Syndrome (4) 1489–1496
Carroll, B.J., see Myung, W. (1) 283–292
Carter, L., see Arnerić, S.P. (1) 19–35
Castillo, S.S., see de la Rubia Ortí, J.E. (3) 899–903
Castillo-Carranza, D.L., see Nilson, A.N. (3) 1083–1099
Cavallaro, S., see Cuccaro, D. (1) 37–52
Cayer, A.-M., see Bergeron, D. (4) 1335–1337
Cea, M., see Monacelli, F. (4) 1295–1306
Cebers, G., R.C. Alexander, S.B. Haeberlein, D. Han, R. Goldwater, L. Ereshefsky, T. Olsson, N. Ye, L. Rosen, M. Russell, J. Maltby, S. Eketjäll and A.R. Kugler, AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer’s Disease (3) 1039–1053
Cerami, C., A. Dodich, L. Greco, S. Iannaccone, G. Magnani, A. Marcone, E. Pelagallo, R. Santangelo, S.F. Cappa and D. Perani, The Role of Single-Subject Brain Metabolic Patterns in the Early Differential Diagnosis of Primary Progressive Aphasias and in Prediction of Progression to Dementia (1) 183–197
Cercignani, M., see Serra, L. (1) 421–430
Cerulli, G., see Crispoltoni, L. (3) 1005–1017
Chabot, J., see Beauchet, O. (3) 965–971
Chami, M., see Prete, D.D. (4) 1549–1570
Chang, J., see Chang, P. (1) 77–87
Chang, P., X. Li, C. Ma, S. Zhang, Z. Liu, K. Chen, L. Ai, J. Chang and Z. Zhang, The Effects of an APOE Promoter Polymorphism on Human White Matter Connectivity during Non-Demented Aging (1) 77–87
Chang, X., see Fraser, M.D. (4) 1321–1325
Chapman, B.P., see Lin, F., (2) 669–678
Chattat, R., see Mariani, E. (4) 1621–1638
Chau, S.A., N. Herrmann, C. Sherman, J. Chung, M. Eizenman, A. Kiss and K.L. Lanctôt, Visual Selective Attention Toward Novel Stimuli Predicts Cognitive Decline in Alzheimer’s Disease Patients (4) 1339–1349
Chaudhry, F.A., see Idland, A.-V. (1) 371–379
Checler, F., see Prete, D.D. (4) 1549–1570
Chen, K., see Chang, P. (1) 77–87
Chen, K., see Sun, L. (2) 777–785
Chen, T., see Zhuang, X. (3) 1101–1108
Chen, Y., see Zhuang, X. (3) 1101–1108
Cheon, H.-S., see Shim, S.-M. (1) 293–301
Cheran, G., see Huey, E.D.(2) 551–558
Chiasserini, D., see Lewczuk, P. (1) 159–170
Chiasserini, D., see Sancesario, G.M. (4) 1659–1666
Cho, K.H., see Kim, Y. (2) 485–495
Choi, B., see An, H. (2) 727–735
Choi, J., see Myung, W. (1) 283–292
Choi, S.H., see Myung, W. (1) 283–292
Choi, Y., see Ryu, H.J. (4) 1395–1401
Chong, S.A., see Peh, C.X. (2) 823–833
Christian, B.T., see Darst, B.F. (2) 473–484
Chua, B.Y., see Peh, C.X. (2) 823–833
Chung, J., see Chau, S.A. (4) 1339–1349
Chung, J.W., see Myung, W. (1) 283–292
Cittadella R., see Cuccaro, D. (1) 37–52
Claassen, J., see Jansen, W.J. (2) 679–689
Clare, L., see Yates, J.A., (3) 1183–1193
Clark, C.N., see Golden, H.L. (3) 933–949
Clerx, L., see Freeze, W.M. (1) 333–342
Clodomiro, A., see Cupidi, C. (3) 1249–1259
Cohen, M.H., see Golden, H.L. (3) 933–949
Cohen-Manheim, I., G.M. Doniger, R. Sinnreich, E.S. Simon, H. Murad, R. Pinchas-Mizrachi and J.D. Kark Body Mass Index, Height and Socioeconomic Position in Adolescence, Their Trajectories into Adulthood, and Cognitive Function in Midlife (3) 1207–1221
Colao, R., see Cupidi, C. (3) 1249–1259
Comi, C., see Sainaghi, P.P. (1) 59–65
Compta, Y., see Buongiorno, M. (3) 1261–1272
Conidi, M.E., see Cupidi, C. (3) 1249–1259
Constantinides, V., see Paraskevas, G.P. (4) 1453–1461
Coppola, G., see Fong, J.C. (1) 249–258
Corsini, A., see Zimetti, F., (1) 315–320
Coskun, P., P. Helguera, Z. Nemati, R.C. Bohannan, J. Thomas, S.E. Schriner, J. Argueta, E. Doran, D.C. Wallace, I.T. Lott and J. Busciglio, Metabolic and Growth Rate Alterations in Lymphoblastic Cell Lines Discriminate Between Down Syndrome and Alzheimer’s Disease (2) 737–748
Coulson, E.J., see Turnbull, M.T. (3) 1141–1154
Crain, C.N., see Nilson, A.N. (3) 1083–1099
Crispoltoni, L., A.M. Stabile, A. Pistilli, M. Venturelli, G. Cerulli, C. Fonte, N. Smania, F. Schena and M. Rende, Changes in Plasma β-NGF and Its Receptors Expression on Peripheral Blood Monocytes During Alzheimer’s Disease Progression (3) 1005–1017
Crutch, S.J., see Golden, H.L. (3) 933–949
Cuccaro, D., E. Valeria De Marco, R. Cittadella and S. Cavallaro, Copy Number Variants in Alzheimer’s Disease (1) 37–52
Cui, D., see Xie, B. (2) 509–520
Cummings, J., P. Scheltens, I. McKeith, R. Blesa, J.E. Harrison, P.H.F. Bertolucci, K. Rockwood, D. Wilkinson, W. Wijker, D.A. Bennett and R.C. Shah, Effect Size Analyses of Souvenaid in Patients with Alzheimer’s Disease (3) 1131–1139
Cupidi, C., F. Frangipane, M. Gallo, A. Clodomiro, R. Colao, L. Bernardi, M. Anfossi, M.E. Conidi, F. Vasso, S.A.M. Curcio, M. Mirabelli, N. Smirne, G. Torchia, M.G. Muraca, G. Puccio, R. Di Lorenzo, S. Zampieri, M. Romanello, A. Dardis, R.G. Maletta and A.C. Bruni, Role of Niemann-Pick Type C Disease Mutations in Dementia (3) 1249–1259
Curcio, S.A.M., see Cupidi, C. (3) 1249–1259
Cypess, A.M., see Fried, P.J. (1) 89–100
Daffner, K., see Håkansson, K. (2) 645–657
Dal-Pan, A., S. Dudonné, P. Bourassa, M. Bourdoulous, C. Tremblay, Y. Desjardins and F. Calon on behalf of the Neurophenols consortium, Cognitive-Enhancing Effects of a Polyphenols-Rich Extract from Fruits without Changes in Neuropathology in an Animal Model of Alzheimer’s Disease (1) 115–135
Damanhuri, H.A., see Ibrahim, N.F. (2) 597–612
Dardis, A., see Cupidi, C. (3) 1249–1259
Darst, B.F., R.L. Koscik, A.M. Racine, J.M. Oh, R.A. Krause, C.M. Carlsson, H. Zetterberg, K. Blennow, B.T. Christian, B.B. Bendlin, O.C. Okonkwo, K.J. Hogan, B.P. Hermann, M.A. Sager, S. Asthana, S.C. Johnson and C.D. Engelman, Pathway-Specific Polygenic Risk Scores as Predictors of Amyloid-b Deposition and Cognitive Function in a Sample at Increased Risk for Alzheimer’s Disease (2) 473–484
Davey, C.S., see Vemuri, P. (3) 1069–1082
Davies, J.R.T., see Fraser, M.D. (4) 1321–1325
Davis, J., see Anderson, M. (3) 1109–1121
Dawes, M., see McClure, R. (2) 797–811
De Blasi, R., see Papazacharias, A. (3) 973–979
De Deyn, P.P., see Dekens, D.W. (2) 763–776
De Deyn, P.P., see Goossens, J. (1) 53–58
de França Bram, J.M., see Sarno, T.A. (4) 1445–1451
de la Monte, S.M., M. Tong, I. Schiano and J. Didsbury, Improved Brain Insulin/IGF Signaling and Reduced Neuroinflammation with T3D-959 in an Experimental Model of Sporadic Alzheimer’s Disease (2) 849–864
de la Rubia Ortí, J.E., S.S. Castillo, M. Benlloch, M.J. Rochina, S.C. Arreche and M.P. García-Pardo
De La Sablonnière, J., see Bergeron, D. (4) 1335–1337
de La Sayette, V., see Duclos, H. (2) 459–463
De, S., see Fisher, C.L. (1) 391–410
Dean, R., see Arnerić, S.P. (1) 19–35
Debayle, D., see Prete, D.D. (4) 1549–1570
Dekens, D.W., P.J.W. Naudé, S. Engelborghs, Y. Vermeiren, D. Van Dam, R.C.O. Voshaar, U.L.M. Eisel and P.P. De Deyn, Neutrophil Gelatinase-Associated Lipocalin and its Receptors in Alzheimer’s Disease (AD) Brain Regions: Differential Findings in AD with and without Depression (2) 763–776
Delgado, C., see Slachevsky, A. (4) 1595–1603
Demirel, H., see Beheshti, I. (4) 1571–1582
Dengler-Crish, C.M., M.A. Smith and G.N. Wilson, Early Evidence of Low Bone Density and Decreased Serotonergic Synthesis in the Dorsal Raphe of a Tauopathy Model of Alzheimer’s Disease (4) 1605–1619
Desgranges, B., see Duclos, H. (2) 459–463
Desjardins Y., see Dal-Pan, A. (1) 115–135
Devanand, D.P., see Huey, E.D.(2) 551–558
Dewing, A.S.T., see Rueli, R.H.L.H. (2) 749–762
Di Domenico, C., see Serra, L. (1) 421–430
Di Lorenzo, R., see Cupidi, C. (3) 1249–1259
Di Santo, S.G., see Sancesario, G.M. (4) 1659–1666
Dichgans, M., see Araque Caballero, M.Á. (1) 343–358
Didsbury, J., see de la Monte, S.M. (2) 849–864
Dierks, T., see Andreotti, J. (3) 981–993
Dobson, R.J.B., see Voyle, N. (4) 1417–1427
Dodich, A., see Cerami, C. (1) 183–197
Domínguez-Prieto, M., A. Velasco, L. Vega, A. Tabernero and J.M. Medina, Aberrant Co-localization of Synaptic Proteins Promoted by Alzheimer’s Disease Amyloid-β Peptides: Protective Effect of Human Serum Albumin (1) 171–182
Doniger, G.M., see Cohen-Manheim, I. (3) 1207–1221
Dopper, E.G.P., see Hafkemeijer, A. (2) 521–537
Doraiswamy, P.M., see Lin, K.A. (3) 1123–1130
Doran, E., see Coskun, P. (2) 737–748
Doverskog, M., see Philippens, I.H. (1) 101–113
Dragano, N., see Kara, K. (1) 359–369
Dronse, J., K. Fliessbach, G.N. Bischof, B. von Reutern, J. Faber, J. Hammes, G. Kuhnert, B. Neumaier, O.A. Onur, J. Kukolja, T. van Eimeren, F. Jessen, G.R. Fink, T. Klockgether and A. Drzezga, In vivo Patterns of Tau Pathology, Amyloid-b Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimer’s Disease (2) 465–471
Drzezga, A., see Dronse, J. (2) 465–471
Du, H., see Gauba, E. (4) 1351–1362
Dubois, A., see Leger, D. (1) 321–331
Ducharme, F., see Wawrziczny, E. (2) 703–716
Duclos, H., V. de La Sayette, A.-L. Bonnet, A. Viard, F. Eustache, B. Desgranges and M. Laisney, Social Cognition in the Frontal Variant of Alzheimer’s Disease: A Case Study (2) 459–463
Dudonné, S., see Dal-Pan, A. (1) 115–135
Duffy, J.R., see Krishnan, K. (3) 1019–1029
Duque, J.E., see Ochoa, J.F. (3) 1195–1205
Durani, L.W., see Ibrahim, N.F. (2) 597–612
Durgerian, S., see Reiter, K. (4) 1363–1377
Edwards, K., see Savica, R. (2) 559–567
Eichler, T., see Wucherer, D. (2) 691–701
Eisel, U.L.M., see Dekens, D.W. (2) 763–776
Eizenman, M., see Chau, S.A. (4) 1339–1349
Eketjäll, S., see Cebers, G. (3) 1039–1053
Elbaz, M., see Leger, D. (1) 321–331
Elbing, U., see Muller, S. (4) 1463–1469
Engelborghs, S., see Arnerić, S.P. (1) 19–35
Engelborghs, S., see Dekens, D.W. (2) 763–776
Engelborghs, S., see Goossens, J. (1) 53–58
Engelborghs, S., see Lewczuk, P. (1) 159–170
Engelman, C.D., see Darst, B.F. (2) 473–484
Engels, Y., see Mariani, E. (4) 1621–1638
English, K.C., see Nilson, A.N. (3) 1083–1099
Erbel, R., see Kara, K. (1) 359–369
Ereshefsky, L., see Cebers, G. (3) 1039–1053
Eri, L.M., see Idland, A.-V. (1) 371–379
Ermani, M., see Cagnin, A. (4) 1529–1536
Eusebi, P., see Lewczuk, P. (2) 813–822
Eustache, F., see Duclos, H. (2) 459–463
Evdokimidis, I., see Paraskevas, G.P. (4) 1453–1461
Ewers, M., see Araque Caballero, M.Á. (1) 343–358
Faber, J., see Dronse, J. (2) 465–471
Fagan, A.M., see Lewczuk, P. (2) 813–822
Fargeau, M.-N., see Arroyo-Anlló, E.M. (4) 1437–1443
Farías, G.A., see Slachevsky, A. (4) 1595–1603
Farías, M., see Slachevsky, A. (4) 1595–1603
Favari, E., see Zimetti, F., (1) 315–320
Feng, T.L., see Robillard, J.M. (1) 219–229
Fenoglio, C., see Sainaghi, P.P. (1) 59–65
Fernández, M., see Buongiorno, M. (3) 1261–1272
Fernández, S., see Carmona-Iragui, M. (4) 1489–1496
Fernandez, Y., see Buongiorno, M. (3) 1261–1272
Ferreira, D., see Rivero-Santana, A. (2) 625–644
Ferrer, I., see Gamir-Morralla, A. (4) 1327–1333
Ferri, N., see Zimetti, F., (1) 315–320
Fink, G.R., see Dronse, J. (2) 465–471
Fischer, C.E., see Kim, J. (1) 381–389
Fischer, C.E., see Sennik, S. (4) 1519–1528
Fisher, C.L., R.J. Resnick, S. De, L.A. Acevedo, K.P. Lu, F.C. Schroeder and L.K. Nicholson, Cyclic cis-Locked Phospho-Dipeptides Reduce Entry of AβPP into Amyloidogenic Processing Pathway (1) 391–410
Fitipaldi, S., see Abrevaya, S. (4) 1429–1435
Flach, K., see Lewczuk, P. (1) 159–170
Fleiner, T., S. Leucht, H. Förstl, W. Zijlstra and P. Haussermann, Effects of Short-Term Exercise Interventions on Behavioral and Psychological Symptoms in Patients with Dementia: A Systematic Review (4) 1583–1594
Fliessbach, K., see Dronse, J. (2) 465–471
Flores, P., see Slachevsky, A. (4) 1595–1603
Folarin, A., see Voyle, N. (4) 1417–1427
Fong, J.C., J.C. Rojas, J. Bang, A. Legati, K.P. Rankin, S. Forner, Z.A. Miller, A.M. Karydas, G. Coppola, C.K. Grouse, J. Ralph, B.L. Miller and M.D. Geschwind, Genetic Prion Disease Caused by PRNP Q160X Mutation Presenting with an Orbitofrontal Syndrome, Cyclic Diarrhea, and Peripheral Neuropathy (1) 249–258
Fonte, C., see Crispoltoni, L. (3) 1005–1017
Forlenza, O.V., see Sarno, T.A. (4) 1445–1451
Forner, S., see Fong, J.C. (1) 249–258
Förstl, H., see Fleiner, T. (4) 1583–1594
Fortea, J., see Carmona-Iragui, M. (4) 1489–1496
Fortea, J., see Gamir-Morralla, A. (4) 1327–1333
Foscarin, S., see Raha, A.A. (1) 199–217
Foulkes, A.J.M., see Golden, H.L. (3) 933–949
Foxe, J.J., see Lin, F., (2) 669–678
Fragiacomo, F., see Cagnin, A. (4) 1529–1536
Franco, O.H., see Wolters, F.J. (3) 893–897
Frangipane, F., see Cupidi, C. (3) 1249–1259
Fraser, M.D., J.R.T. Davies and X. Chang, New Gold in Them Thar Hills: Testing a Novel Supply Route for Plant-Derived Galanthamine (4) 1321–1325
Freeze, W.M., H.I.L. Jacobs, E.H. Gronenschild, J.F.A. Jansen, S. Burgmans, P. Aalten, L. Clerx, S.J. Vos, M.A. van Buchem, F. Barkhof, W.M. van der Flier, M.M. Verbeek, M.O. Rikkert, W.H. Backes and F.R. Verhey, on behalf of the LeARN project, White Matter Hyperintensities Potentiate Hippocampal Volume Reduction in Non-Demented Older Individuals with Abnormal Amyloid-β (1) 333–342
Fried, P.J., L. Schilberg, A.-K. Brem, S. Saxena, B. Wong, A.M. Cypess, E.S. Horton and A. Pascual-Leone, Humans with Type-2 Diabetes Show Abnormal Long-Term Potentiation-Like Cortical Plasticity Associated with Verbal Learning Deficits (1) 89–100
Friedland, R.P., see Raha, A.A. (1) 199–217
Frihagen, F., see Idland, A.-V. (1) 371–379
Fujikura, M., see Iwahara, N. (3) 1235–1247
Galimberti, D., see Sainaghi, P.P. (1) 59–65
Galimberti, D., see Zimetti, F., (1) 315–320
Gallo, M., see Cupidi, C. (3) 1249–1259
Galvin, J.E., see Ryu, H.J. (4) 1395–1401
Gamir-Morralla, A., O. Belbin, J. Fortea, D. Alcolea, I. Ferrer, A. Lleó and T. Iglesias, Kidins220 Correlates with Tau in Alzheimer’s Disease Brain and Cerebrospinal Fluid (4) 1327–1333
García, J.R., see Buongiorno, M. (3) 1261–1272
Garcíaa, A.M., see Abrevaya, S. (4) 1429–1435
García-Alcocer, G., see Mendiola-Precoma, J. (3) 1273–1283
García-Pardo, M.P., see de la Rubia Ortí, J.E. (3) 899–903
Garrido, C., see Slachevsky, A. (4) 1595–1603
Gattaz, W.F., see Sarno, T.A. (4) 1445–1451
Gauba, E., L. Guo and H. Du, Cyclophilin D Promotes Brain Mitochondrial F1FO ATP Synthase Dysfunction in Aging Mice (4) 1351–1362
Gay, A.S., see Prete, D.D. (4) 1549–1570
Gažová, I., see Pařízková, M. (3) 951–964
Gelpi, E., see Grau-Rivera, O. (1) 431–443
Genius, J., see Arnerić, S.P. (1) 19–35
Gerson, J.E., see Nilson, A.N. (3) 1083–1099
Geschwind, M.D., see Fong, J.C. (1) 249–258
Ghidoni, R., see H. Bea Kuiperij, (2) 585–595
Gielen, J., see Goossens, J. (1) 53–58
Gil, R., see Arroyo-Anlló, E.M. (4) 1437–1443
Giulietti, G., see Serra, L. (1) 421–430
Gobom, J., see Russell, C.L. (1) 303–313
Goeman, J., see Goossens, J. (1) 53–58
Golden, H.L., C.N. Clark, J.M. Nicholas, M.H. Cohen, C.F. Slattery, R.W. Paterson, A.J.M. Foulkes, J.M. Schott, C.J. Mummery, S.J. Crutch and J.D. Warren, Music Perception in Dementia (3) 933–949
Goldwater, R., see Cebers, G. (3) 1039–1053
Gomes, K.B., see Miranda, L.F.J.R. (2) 539–549
Gomez, D., see Abrevaya, S. (4) 1429–1435
Gong, Q., see Hilt, S. (4) 1667–1681
Goossens, J., J. Laton, J.V. Schependom, J. Gielen, H. Struyfs, S. Van Mossevelde, T. Van den Bossche, J. Goeman, P.P. De Deyn, A. Sieben, J.-J. Martin, C. Van Broeckhoven, J. van der Zee, S. Engelborghs and G. Nagels, EEG Dominant Frequency Peak Differentiates Between Alzheimer’s Disease and Frontotemporal Lobar Degeneration (1) 53–58
Gordon, M.F., see Arnerić, S.P. (1) 19–35
Gore, J.C., see McClure, R. (2) 797–811
Grafman, J., see Huey, E.D.(2) 551–558
Granholm, A.-C., see Håkansson, K. (2) 645–657
Grau-Rivera, O., A. Calvo, N. Bargalló, G.C. Monté, C. Nos, A. Lladó, J.L. Molinuevo, E. Gelpi and R. Sánchez-Valle, Quantitative Magnetic Resonance Abnormalities in Creutzfeldt-Jakob Disease and Fatal Insomnia (1) 431–443
Greco, L., see Cerami, C. (1) 183–197
Grieder, M., see Andreotti, J. (3) 981–993
Gronenschild, E.H., see Freeze, W.M. (1) 333–342
Grouse, C.K., see Fong, J.C. (1) 249–258
Guo, J.-P., see Lee, M. (3) 1175–1182
Guo, L., see Gauba, E. (4) 1351–1362
Gupta, P., see Nilson, A.N. (3) 1083–1099
Gureviciene, I., K. Gurevicius, E. Mugantseva, M. Kislin, L. Khiroug and H. Tanila, Amyloid Plaques Show Binding Capacity of Exogenous Injected Amyloid-β (1) 147–157
Gurevicius, K., see Gureviciene, I. (1) 147–157
Guzmán-Martínez, L., see Slachevsky, A. (4) 1595–1603
Haapasalo, A., see Laiterä, T. (3) 995–1003
Haeberlein, S.B., see Cebers, G. (3) 1039–1053
Hafkemeijer, A., C. Möller, E.G.P. Dopper, L.C. Jiskoot, A.A. van den Berg-Huysmans, J.C. van Swieten, W.M. van der Flier, H. Vrenken, Y.A.L. Pijnenburg, F. Barkhof, P. Scheltens, J. van der Grond and S.A.R.B. Rombouts, A Longitudinal Study on Resting State Functional Connectivity in Behavioral Variant Frontotemporal Dementia and Alzheimer’s Disease (2) 521–537
Hagen, C., see Savica, R. (2) 559–567
Håkansson, K., A. Ledreux, K. Daffner, Y. Terjestam, P. Bergman, R. Carlsson, M. Kivipelto, B. Winblad, A.-C. Granholm and A.K.H. Mohammed, BDNF Responses in Healthy Older Persons to 35 Minutes of Physical Exercise, Cognitive Training, and Mindfulness: Associations with Working Memory Function (2) 645–657
Hall, A., see Pekkala, T. (3) 1055–1067
Ham, J.H., see Kim, Y. (2) 485–495
Hamaguchi, T., see Noguchi-Shinohara, M. (3) 905–913
Hamasaki, H., H. Honda, T. Okamoto, S. Koyama, S.O. Suzuki, T. Ohara, T. Ninomiya, Y. Kiyohara and T. Iwaki, Recent Increases in Hippocampal Tau Pathology in the Aging Japanese Population: The Hisayama Study (2) 613–624
Hamezah, H.S., see Ibrahim, N.F. (2) 597–612
Hammes, J., see Dronse, J. (2) 465–471
Han, D., see Cebers, G. (3) 1039–1053
Han, J.W., H. Lee, J.W. Hong, K. Kim, T. Kim, H.J. Byun, J.W. Ko, J.C. Youn, S.-H. Ryu, N.-J. Lee, C.-U. Pae and K.W. Kim, Multimodal Cognitive Enhancement Therapy for Patients with Mild Cognitive Impairment and Mild Dementia: A Multi- Center, Randomized, Controlled, Double-Blind, Crossover Trial (2) 787–796
Han, J.W., see Jacob, L. (1) 259–267
Han, J.-Y., see Ryu, H.J. (4) 1395–1401
Han, S.-H., see An, H. (2) 727–735
Han, S.-H., see Myung, W. (1) 283–292
Han, S.-H., see Ryu, H.J. (4) 1395–1401
Handels, R.L.H., see Jansen, W.J. (2) 679–689
Hansson, K., see Russell, C.L. (1) 303–313
Hansson, O., see Idland, A.-V. (1) 371–379
Hardman, R.J., see Kennedy, G. (1) 1–18
Harrington, C.A., see Lusardi, T.A. (3) 1223–1233
Harrison, J.E., see Cummings, J. (3) 1131–1139
Haussermann, P., see Fleiner, T. (4) 1583–1594
He, R., see Tong, Z. (3) 1031–1038
Helguera, P., see Coskun, P. (2) 737–748
Helisalmi, S., see Laiterä, T. (3) 995–1003
Henderson, J.W., see Raha, A.A. (1) 199–217
Hermann, B.P., see Darst, B.F. (2) 473–484
Hernández, A.M., see Ochoa, J.F. (3) 1195–1205
Herrmann, N., see Chau, S.A. (4) 1339–1349
Hertel, J., see Wucherer, D. (2) 691–701
Heymann, P., see Muller, S. (4) 1463–1469
Hideg, K., see Hilt, S. (4) 1667–1681
Hijioka, M., see Kitamura, Y. (1) 67–72
Hilt, S., T. Tang, J.H. Walton, M. Budamagunta, I. Maezawa, T. Kálai, K. Hideg, V. Singh, H. Wulff, Q. Gong, L.-W. Jin, A. Louie and J.C. Voss, A Metal-Free Method for Producing MRI Contrast at Amyloid-b (4) 1667–1681
Hiltunen, M., see Laiterä, T. (3) 995–1003
Hiltunen, M., see Russell, C.L. (1) 303–313
Hisahara, S., see Iwahara, N. (3) 1235–1247
Hitchcock, J., see Arnerić, S.P. (1) 19–35
Hoff, E., see Jansen, W.J. (2) 679–689
Hoffmann, W., see Teipel, S.J. (4) 1379–1394
Hoffmann, W., see Wucherer, D. (2) 691–701
Hofman, A., see Wolters, F.J. (3) 893–897
Hogan, K.J., see Darst, B.F. (2) 473–484
Hollman, J.H., see Savica, R. (2) 559–567
Holzer, M., see Lewczuk, P. (1) 159–170
Honda, H., see Hamasaki, H. (2) 613–624
Hong, C.H., see An, H. (2) 727–735
Hong, J.W., see Han, J.W. (2) 787–796
Hoogmoed, J., see Jansen, W.J. (2) 679–689
Hort, J., see Pařízková, M. (3) 951–964
Horton, E.S., see Fried, P.J. (1) 89–100
Horvath, S., see Nemeth,V.L. (3) 865–880
Houston, S., see Petersen, S. (2) 569–574
Huang, F. see Shen, Y. (2) 835–847
Huey, E.D., S. Lee, G. Cheran, J. Grafman, D.P. Devanand and for the Alzheimer’s Disease Neuroimaging Initiative, Brain Regions Involved in Arousal and Reward Processing are Associated with Apathy in Alzheimer’s Disease and Frontotemporal Dementia (2) 551–558
Huovinen, J., see Laiterä, T. (3) 995–1003
Iannaccone, S., see Cerami, C. (1) 183–197
Ibáñez, A., see Abrevaya, S. (4) 1429–1435
Ibrahim, N.F., D. Yanagisawa, L.W. Durani, H.S. Hamezah, H.A. Damanhuri, W.Z.W. Ngah, M. Tsuji, Y. Kiuchi, K. Ono and I. Tooyama, Tocotrienol-Rich Fraction Modulates Amyloid Pathology and Improves Cognitive Function in AβPP/PS1 Mice (2) 597–612
Idland, A.-V., T.B. Wyller, R. Støen, L.M. Eri, F. Frihagen, J. Ræder, F.A. Chaudhry, O. Hansson, H. Zetterberg, K. Blennow, N. Bogdanovic, A. Brækhus and L.O. Watne, Preclinical Amyloid-β and Axonal Degeneration Pathology in Delirium (1) 371–379
Igase, K., see Igase, M. (4) 1481–1487
Igase, M., M. Ohara, K. Igase, T. Kato, Y. Okada, M. Ochi, Y. Tabara, K. Kohara and Y. Ohyagi, Skin Autofluorescence Examination as a Diagnostic Tool for Mild Cognitive Impairment in Healthy People (4) 1481–1487
Iglesias, T., see Gamir-Morralla, A. (4) 1327–1333
Ikeda, T., see Noguchi-Shinohara, M. (3) 905–913
Ikram, M.A., see Wolters, F.J. (3) 893–897
Imbimbo, B.P., see Papazacharias, A. (3) 973–979
Impact of the Relationship of Stress and the Immune System in the Appearance of Alzheimer’s Disease (3) 899–903
Inden, M., see Kitamura, Y. (1) 67–72
Ishii, K., see Kazui, H. (4) 1403–1416
Iwahara, N., S. Hisahara, J. Kawamata, A. Matsumura, K. Yokokawa, T. Saito, M. Fujikura, T. Manabe, H. Suzuki, T. Matsushita, S. Suzuki and S. Shimohama, Role of Suppressor of Cytokine Signaling 3 (SOCS3) in Altering Activated Microglia Phenotype in APPswe/PS1dE9 Mice (3) 1235–1247
Iwaki, T., see Hamasaki, H. (2) 613–624
Jääskeläinen, J.E., see Laiterä, T. (3) 995–1003
Jack Jr, C.R., see Vemuri, P. (3) 1069–1082
Jack Jr., C.R., see Krishnan, K. (3) 1019–1029
Jacob, L., J.W. Han, T.H. Kim, J.H. Park, S.B. Lee, J.J. Lee, S.-H. Ryu, S.-K. Kim, J.C. Yoon, J.H. Jhoo, J.L. Kim, K.P. Kwak, S.W. Moon, B.J. Kim, D.Y. Lee and K.W. Kim, How Different are Quality of Life Ratings for People with Dementia Reported by Their Family Caregivers from Those Reported by the Patients Themselves? (1) 259–267
Jacobs, A., see Lin, F., (2) 669–678
Jacobs, H.I.L., see Freeze, W.M. (1) 333–342
Jang, J.-W., see Kim, H.-R. (1) 137–146
Jansen, J.F.A., see Freeze, W.M. (1) 333–342
Jansen, W.J., R.L.H. Handels, P.J. Visser, P. Aalten, F. Bouwman, J. Claassen, P. van Domburg, E. Hoff, J. Hoogmoed, A.F.G. Leentjens, M.O. Rikkert, A.M. Oleksik, M. Smid, P. Scheltens, C. Wolfs, F. Verhey and I.H.G.B. Ramakers, The Diagnostic and Prognostic Value of Neuropsychological Assessment in Memory Clinic Patients (2) 679–689
Janve, V., see McClure, R. (2) 797–811
Jeon, J.-P., see Shim, S.-M. (1) 293–301
Jerome, W.G., see McClure, R. (2) 797–811
Jessen, F., see Dronse, J. (2) 465–471
Jhoo, J.H., see Jacob, L. (1) 259–267
Jia, J., see Tong, Z. (3) 1031–1038
Jiang, G., see Zhuang, X. (3) 1101–1108
Jiang, L., see Xie, B. (2) 509–520
Jin, L.-W., see Hilt, S. (4) 1667–1681
Jiskoot, L.C., see Hafkemeijer, A. (2) 521–537
Jo, C., see Shim, S.-M. (1) 293–301
Joaquim, H.P.G., see Sarno, T.A. (4) 1445–1451
Jöckel, K.-H., see Kara, K. (1) 359–369
Johansson, M., see Philippens, I.H. (1) 101–113
Johnson, S.C., see Darst, B.F. (2) 473–484
Johnston, C., see Voyle, N. (4) 1417–1427
Jokisch, M., see Kara, K. (1) 359–369
Josephs, K.A., see Krishnan, K. (3) 1019–1029
Jr. Laforce, R., see Bergeron, D. (4) 1335–1337
Kabadi, S., see Quarmley, M. (4) 1497–1507
Kálai, T., see Hilt, S. (4) 1667–1681
Kälsch, H., see Kara, K. (1) 359–369
Kanemoto, H., see Kazui, H. (4) 1403–1416
Kang, H.S., see Myung, W. (1) 283–292
Kantarci, K., see Vemuri, P. (3) 1069–1082
Kapaki, E., see Paraskevas, G.P. (4) 1453–1461
Kaplow, J., see Arnerić, S.P. (1) 19–35
Kara, K., A.A. Mahabadi, C. Weimar, A. Winkler, T. Neumann, H. Kälsch, N. Dragano, S. Moebus, R. Erbel, K.-H. Jöckel and M. Jokisch, N-Terminal Pro-B Type Natriuretic Peptide is Associated with Mild Cognitive Impairment in the General Population (1) 359–369
Kark, J.D., see Cohen-Manheim, I. (3) 1207–1221
Karydas, A.M., see Fong, J.C. (1) 249–258
Kasselimis, D., see Paraskevas, G.P. (4) 1453–1461
Kato, T., see Igase, M. (4) 1481–1487
Kawamata, J., see Iwahara, N. (3) 1235–1247
Kayed, R., see Nilson, A.N. (3) 1083–1099
Kazui, H., R. Takahashi, Y. Yamamoto, K. Yoshiyama, H. Kanemoto, Y. Suzuki, S. Sato, S. Azuma, T. Suehiro, E. Shimosegawa, K. Ishii and T. Tanaka, Neural Basis of Apathy in Patients with Amnestic Mild Cognitive Impairment (4) 1403–1416
Keller, F., see Teipel, S.J. (4) 1379–1394
Kelly, D.A., see Reiter, K. (4) 1363–1377
Kennedy, G., R.J. Hardman, H. Macpherson, A.B. Scholey and A. Pipingas, How Does Exercise Reduce the Rate of Age-Associated Cognitive Decline? A Review of Potential Mechanisms (1) 1–18
Kennedy, K., see Lee, M. (3) 1175–1182
Kepp, K.P., Ten Challenges of the Amyloid Hypothesis of Alzheimer’s Disease (2) 447–457
Kergoat, M.-J., see Wawrziczny, E. (2) 703–716
Khiroug, L., see Gureviciene, I. (1) 147–157
Kiddle, S.J., see Voyle, N. (4) 1417–1427
Kilimann, I., see Teipel, S.J. (4) 1379–1394
Kilimann, I., see Wucherer, D. (2) 691–701
Kim, B.J., see Jacob, L. (1) 259–267
Kim, B.J., see Kim, H.-R. (1) 137–146
Kim, D.-H., see An, H. (2) 727–735
Kim, D.K., see Myung, W. (1) 283–292
Kim, H.-R., Y.H. Park, J.-W. Jang, S.Y. Park, M.J. Wang, M.J. Baek, B.J. Kim, S. Ahn and S.Y. Kim, Visual Rating of Posterior Atrophy as a Marker of Progression to Dementia in Mild Cognitive Impairment Patients (1) 137–146
Kim, J., T.A. Schweizer, C.E. Fischer and D.G. Munoz, The Role of Cerebrovascular Disease on Cognitive and Functional Status and Psychosis in Severe Alzheimer’s Disease (1) 381–389
Kim, J.L., see Jacob, L. (1) 259–267
Kim, K., see Han, J.W. (2) 787–796
Kim, K.W., see Han, J.W. (2) 787–796
Kim, K.W., see Jacob, L. (1) 259–267
Kim, M., see Ryu, H.J. (4) 1395–1401
Kim, S., see Myung, W. (1) 283–292
Kim, S., see Myung, W. (1) 283–292
Kim, S.-K., see Jacob, L. (1) 259–267
Kim, S.Y., see An, H. (2) 727–735
Kim, S.Y., see Kim, H.-R. (1) 137–146
Kim, S.Y., see Myung, W. (1) 283–292
Kim, S.Y., see Myung, W. (1) 283–292
Kim, T., see Han, J.W. (2) 787–796
Kim, T.H., see Jacob, L. (1) 259–267
Kim, Y., D. Lee, K.H. Cho, J.J. Lee, J.H. Ham, B.S. Ye, S.-K. Lee, J.-M. Lee, Y.H. Sohn and P.H. Lee, Cognitive and Neuroanatomical Correlates in Early Versus LateOnset Parkinson’s Disease Dementia (2) 485–495
Kimoto, Y., see Kitamura, Y. (1) 67–72
Kincses, Z.T., see Nemeth,V.L. (3) 865–880
Király, A., see Nemeth,V.L. (3) 865–880
Kislin, M., see Gureviciene, I. (1) 147–157
Kiss, A., see Chau, S.A. (4) 1339–1349
Kitamura, Y., M. Inden, Y. Kimoto, K. Takata, D. Yanagisawa, M. Hijioka, E. Ashihara, I. Tooyama, S. Shimohama and H. Ariga, Effects of a DJ-1-Binding Compound on Spatial Learning and Memory Impairment in a Mouse Model of Alzheimer’s Disease (1) 67–72
Kiuchi, Y., see Ibrahim, N.F. (2) 597–612
Kivipelto, M., see Håkansson, K. (2) 645–657
Kivipelto, M., see Pekkala, T. (3) 1055–1067
Kiyohara, A.C., see Rueli, R.H.L.H. (2) 749–762
Kiyohara, Y., see Hamasaki, H. (2) 613–624
Klockgether, T., see Dronse, J. (2) 465–471
Klöppel, S., see Araque Caballero, M.Á. (1) 343–358
Knopman, D.S., see Savica, R. (2) 559–567
Knopman, D.S., see Vemuri, P. (3) 1069–1082
Ko, J.W., see Han, J.W. (2) 787–796
Kobayashi, H., see Moss, D.E. (3) 1285–1294
Koch, G., see Serra, L. (1) 421–430
Koh, Y.H., see Shim, S.-M. (1) 293–301
Kohara, K., see Igase, M. (4) 1481–1487
Komatsu, J., see Noguchi-Shinohara, M. (3) 905–913
Koopmans, R., see Mariani, E. (4) 1621–1638
Kornhuber, J., see Lewczuk, P. (1) 159–170
Kornhuber, J., see Lewczuk, P. (2) 813–822
Koscik, R.L., see Darst, B.F. (2) 473–484
Koudstaal, P.J., see Wolters, F.J. (3) 893–897
Kourtidou, E., see Paraskevas, G.P. (4) 1453–1461
Kovac, A., see Banks, W.A. (1) 411–419
Koyama, S., see Hamasaki, H. (2) 613–624
Krause, R.A., see Darst, B.F. (2) 473–484
Krishnan, K., M.M. Machulda, J.L. Whitwell, A.M. Butts, J.R. Duffy, E.A. Strand, M.L. Senjem, A.J. Spychalla, C.R. Jack Jr., V.J. Lowe and K.A. Josephs, Varying Degrees of Temporoparietal Hypometabolism on FDG-PET Reveal Amyloid-Positive Logopenic Primary Progressive Aphasia is not a Homogeneous Clinical Entity (3) 1019–1029
Kuceyeski, A., see Pandya, S. (4) 1639–1657
Kugler, A.R., see Cebers, G. (3) 1039–1053
Kuhnert, G., see Dronse, J. (2) 465–471
Kukolja, J., see Dronse, J. (2) 465–471
Kurumatani, N., see Okamoto, N. (2) 575–583
Küsters, B., see H. Bea Kuiperij, (2) 585–595
Kuuluvainen, L., M. Pöyhönen, P. Pasanen, M. Siitonen, J. Rummukainen, P.J. Tienari, A. Paetau and L. Myllykangas, A Novel Loss-of-Function GRN Mutation p.(Tyr229*): Clinical and Neuropathological Features (3) 1167–1174
Kwak, K.P., see Jacob, L. (1) 259–267
Laatikainen, T., see Pekkala, T. (3) 1055–1067
Lacas-Gervais, S., see Prete, D.D. (4) 1549–1570
Lachmann, I., see Lewczuk, P. (1) 159–170
Laczó, J., see Pařízková, M. (3) 951–964
Laffon, B., see Valdiglesias, V. (4) 1509–1517
Laisney, M., see Duclos, H. (2) 459–463
Laiterä, T., J. Paananen, S. Helisalmi, T. Sarajärvi, J. Huovinen, M. Laitinen, T. Rauramaa, I. Alafuzoff, A.M. Remes, H. Soininen, A. Haapasalo, J.E. Jääskeläinen, V. Leinonen and M. Hiltunen, Effects of Alzheimer’s Disease-Associated Risk Loci on Amyloid-β Accumulation in the Brain of Idiopathic Normal PressureHydrocephalus Patients (3) 995–1003
Laitinen, M., see Laiterä, T. (3) 995–1003
Lakshminarayan, K., see Vemuri, P. (3) 1069–1082
Lanctôt, K.L., see Chau, S.A. (4) 1339–1349
Langlois, X., see Waldron, A.-M. (4) 1537–1548
Lapidus, J.A., see Lusardi, T.A. (3) 1223–1233
Laske, C., see Muller, S. (4) 1463–1469
Laton, J., see Goossens, J. (1) 53–58
Lattanzio, F., see Rumeileh, S.A. (4) 1471–1480
Launay, C.P., see Beauchet, O. (3) 965–971
Lawrence, C.B., see Martins, I.V.A. (3) 915–932
Ledreux, A., see Håkansson, K. (2) 645–657
Lee, C., see Myung, W. (1) 283–292
Lee, D., see Kim, Y. (2) 485–495
Lee, D.Y., see Jacob, L. (1) 259–267
Lee, H., see Han, J.W. (2) 787–796
Lee, J.-H., see Myung, W. (1) 283–292
Lee, J.J., see Jacob, L. (1) 259–267
Lee, J.J., see Kim, Y. (2) 485–495
Lee, J.-M., see Kim, Y. (2) 485–495
Lee, M., J.-P. Guo, K. Kennedy, E.G. McGeer and P.L. McGeer, A Method for Diagnosing Alzheimer’s Disease Based on Salivary Amyloid-β Protein 42 Levels (3) 1175–1182
Lee, N.-J., see Han, J.W. (2) 787–796
Lee, P.H., see Kim, Y. (2) 485–495
Lee, S., see Huey, E.D.(2) 551–558
Lee, S.B., see Jacob, L. (1) 259–267
Lee, S.-K., see Kim, Y. (2) 485–495
Leentjens, A.F.G., see Jansen, W.J. (2) 679–689
Legati, A., see Fong, J.C. (1) 249–258
Leger, D., M. Elbaz, A. Dubois, S. Rio, H. Mezghiche, P. Carita, J. Stemmelin and M. Strauss, Alzheimer’s Disease Severity is Not Significantly Associated with Short Sleep: Survey by Actigraphy on 208 Mild and Moderate Alzheimer’s Disease Patients (1) 321–331
Leinonen, V., see Laiterä, T. (3) 995–1003
Lelental, N., see Lewczuk, P. (1) 159–170
Lerch, O., see Pařízková, M. (3) 951–964
Leucht, S., see Fleiner, T. (4) 1583–1594
Levinoff, E.J., see Beauchet, O. (3) 965–971
Lewczuk, P., A. Matzen, K. Blennow, L. Parnetti, J.L. Molinuevo, P. Eusebi, J. Kornhuber, J.C. Morris and A.M. Fagan, Cerebrospinal Fluid Ab42/40 Corresponds Better than Ab42 to Amyloid PET in Alzheimer’s Disease (2) 813–822
Lewczuk, P., N. Lelental, I. Lachmann, M. Holzer, K. Flach, S. Brandner, S. Engelborghs, C.E. Teunissen, H. Zetterberg, J.L. Molinuevo, B. Mroczko, K. Blennow, J. Popp, L. Parnetti, D. Chiasserini, A. Perret-Liaudet, P. Spitzer, J.M. Maler and J. Kornhuber, Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer’s Disease: Analytical and Diagnostic Characterization (1) 159–170
Li, B., see McClure, R. (2) 797–811
Li, H., see Tong, Z. (3) 1031–1038
Li, Q., see Zhang, Y.-P. (2) 497–507
Li, X., see Chang, P. (1) 77–87
Li, X., see Sun, L. (2) 777–785
Li, X.-M., see Wang, Y. (4) 1683–1692
Lim, N.K.H., see Shen, Y. (2) 835–847
Lim, S.-W., see Myung, W. (1) 283–292
Lin, F., P. Ren, R.Y. Lo, B.P. Chapman, A. Jacobs, T.M. Baran, A.P. Porsteinsson and J.J. Foxe for the Alzheimer’s Disease Neuroimaging Initiative, Insula and Inferior Frontal Gyrus’ Activities Protect Memory Performance Against Alzheimer’s Disease Pathology in Old Age (2) 669–678
Lin, K.A., C. Rundel, P.M. Doraiswamy, for the Alzheimer’s Disease Neuroimaging Initiative, Serum SHBG Levels are not Associated with Longitudinal Cognitive Decline in Mild Cognitive Impairment (3) 1123–1130
Lind, B., see Lusardi, T.A. (3) 1223–1233
Liu, W., see Xie, B. (2) 509–520
Liu, Z., see Chang, P. (1) 77–87
Liu, Z., see Xie, B. (2) 509–520
Lladó, A., see Grau-Rivera, O. (1) 431–443
Lleo, A., see Carmona-Iragui, M. (4) 1489–1496
Lleó, A., see Gamir-Morralla, A. (4) 1327–1333
Lo, R.Y., see Lin, F., (2) 669–678
Logroscino, G., see Papazacharias, A. (3) 973–979
Lombino, F., see Sainaghi, P.P. (1) 59–65
Lomeña, F., see Buongiorno, M. (3) 1261–1272
Lopera, F., see Abrevaya, S. (4) 1429–1435
Lopera, F., see Ochoa, J.F. (3) 1195–1205
López, O.L., see Slachevsky, A. (4) 1595–1603
Lorenzo-López, L., see Valdiglesias, V. (4) 1509–1517
Lötjönen, J., see Pekkala, T. (3) 1055–1067
Lott, I.T., see Coskun, P. (2) 737–748
Louie, A., see Hilt, S. (4) 1667–1681
Lowe, V.J., see Krishnan, K. (3) 1019–1029
Lozupone, M., see Papazacharias, A. (3) 973–979
Lu, K.P., see Fisher, C.L. (1) 391–410
Lundt, E.S., see Vemuri, P. (3) 1069–1082
Luo, H., see Tong, Z. (3) 1031–1038
Luo, W., see Tong, Z. (3) 1031–1038
Lusardi, T.A., J.I. Phillips, J.T. Wiedrick, C.A. Harrington, B. Lind, J.A. Lapidus, J.F. Quinn and J.A. Saugstad, MicroRNAs in Human Cerebrospinal Fluid as Biomarkers for Alzheimer’s Disease (3) 1223–1233
Luthman, J., see Arnerić, S.P. (1) 19–35
Lv, J., see Tong, Z. (3) 1031–1038
Ma, C., see Chang, P. (1) 77–87
Ma, F., see Zhang, Y.-P. (2) 497–507
Maccioni, R.B., see Slachevsky, A. (4) 1595–1603
Machulda, M.M., see Krishnan, K. (3) 1019–1029
Machulda, M.M., see Savica, R. (2) 559–567
Macpherson, H., see Kennedy, G. (1) 1–18
Maezawa, I., see Hilt, S. (4) 1667–1681
Magnani, G., see Cerami, C. (1) 183–197
Mahabadi, A.A., see Kara, K. (1) 359–369
Maikusa, N., see Beheshti, I. (4) 1571–1582
Majerova,P., see Banks, W.A. (1) 411–419
Maler, J.M., see Lewczuk, P. (1) 159–170
Maletta, R.G., see Cupidi, C. (3) 1249–1259
Maltby, J., see Cebers, G. (3) 1039–1053
Manabe, T., see Iwahara, N. (3) 1235–1247
Mañanas, M.A., see Ochoa, J.F. (3) 1195–1205
Mancini, M., see Serra, L. (1) 421–430
Marcone, A., see Cerami, C. (1) 183–197
Mariani, E., R. Chattat, M. Vernooij-Dassen, R. Koopmans and Y. Engels, Care Plan Improvement in Nursing Homes: An Integrative Review (4) 1621–1638
Marková, H., see Pařízková, M. (3) 951–964
Marra, C., see Serra, L. (1) 421–430
Marti, M.J., see Buongiorno, M. (3) 1261–1272
Martin, J.-J., see Goossens, J. (1) 53–58
Martins, I.V.A., J. Rivers-Auty, S.M. Allan and C.B. Lawrence, Mitochondrial Abnormalities and Synaptic Loss Underlie Memory Deficits Seen in Mouse Models of Obesity and Alzheimer’s Disease (3) 915–932
Maseda, A., see Valdiglesias, V. (4) 1509–1517
Maserati, M.S., see Rumeileh, S.A. (4) 1471–1480
Massion, P., see McClure, R. (2) 797–811
Matsuda, H., see Beheshti, I. (4) 1571–1582
Matsumura, A., see Iwahara, N. (3) 1235–1247
Matsunari, I., see Noguchi-Shinohara, M. (3) 905–913
Matsushita, T., see Iwahara, N. (3) 1235–1247
Mattila, J., see Pekkala, T. (3) 1055–1067
Matzen, A., see Lewczuk, P. (2) 813–822
Maurice, T., see Rodríguez Cruz, Y. (1) 231–248
McClure, R., H. Ong, V. Janve, S. Barton, M. Zhu, B. Li, M. Dawes, W.G. Jerome, A. Anderson, P. Massion, J.C. Gore and W. Pham, Aerosol Delivery of Curcumin Reduced Amyloid-β Deposition and Improved Cognitive Performance in a Transgenic Model of Alzheimer’s Disease (2) 797–811
McGeer, E.G., see Lee, M. (3) 1175–1182
McGeer, P.L., see Lee, M. (3) 1175–1182
McKeith, I., see Cummings, J. (3) 1131–1139
Mechanic-Hamilton, D., see Quarmley, M. (4) 1497–1507
Medina, J.M., see Domínguez-Prieto, M. (1) 171–182
Meibach, R., see Arnerić, S.P. (1) 19–35
Mendiola-Precoma, J., K. Padilla, A. Rodríguez-Cruz, L.C. Berumen, R. Miledi and G. García-Alcocer, Theobromine-Induced Changes in A1 Purinergic Receptor Gene Expression and Distribution in a Rat Brain Alzheimer’s Disease Model (3) 1273–1283
Meng, S., see Shen, Y. (2) 835–847
Mezghiche, H., see Leger, D. (1) 321–331
Miao, R., see Zhang, Y.-P. (2) 497–507
Michalowsky, B., see Wucherer, D. (2) 691–701
Mielke, M.M., see Savica, R. (2) 559–567
Miledi, R., see Mendiola-Precoma, J. (3) 1273–1283
Millán-Calenti, J.C., see Valdiglesias, V. (4) 1509–1517
Miller, B.L., see Fong, J.C. (1) 249–258
Miller, Z.A., see Fong, J.C. (1) 249–258
Mirabelli, M., see Cupidi, C. (3) 1249–1259
Miranda, L.F.J.R., K.B. Gomes, P.A.L. Tito, J.N. Silveira, G.A. Pianetti, R.M.D. Byrro, P.R.H. Peles, F.H. Pereira, T.R. Santos, A.G. Assini, V.V. Ribeiro, E.N. Moraes and P. Caramelli, Clinical Response to Donepezil in Mild and Moderate Dementia: Relationship to Drug Plasma Concentration and CYP2D6 and APOE Genetic Polymorphisms (2) 539–549
Mitra, V., see Russell, C.L. (1) 303–313
Moberg, P.J., see Quarmley, M. (4) 1497–1507
Moebus, S., see Kara, K. (1) 359–369
Mohammed, A.K.H., see Håkansson, K. (2) 645–657
Molinuevo, J.L., see Grau-Rivera, O. (1) 431–443
Molinuevo, J.L., see Lewczuk, P. (1) 159–170
Molinuevo, J.L., see Lewczuk, P. (2) 813–822
Möller, C., see Hafkemeijer, A. (2) 521–537
Monacelli, F., M. Cea, R. Borghi, P. Odetti and A. Nencioni, Do Cancer Drugs Counteract Neurodegeneration? Repurposing for Alzheimer’s Disease (4) 1295–1306
Montagnese, S., see Cagnin, A. (4) 1529–1536
Monté, G.C., see Grau-Rivera, O. (1) 431–443
Moon, S.W., see Jacob, L. (1) 259–267
Moon, Y., see Ryu, H.J. (4) 1395–1401
Moraes, E.N., see Miranda, L.F.J.R. (2) 539–549
Moreira, P.I., see Rueli, R.H.L.H. (2) 749–762
Morikawa, M., see Okamoto, N. (2) 575–583
Morris, J.C., see Lewczuk, P. (2) 813–822
Moss, D.E., R.G. Perez and H. Kobayashi, Cholinesterase Inhibitor Therapy in Alzheimer’s Disease: The Limits and Tolerability of Irreversible CNS-Selective Acetylcholinesterase Inhibition in Primates (3) 1285–1294
Mroczko, B., see Lewczuk, P. (1) 159–170
Mubeen, A.M., see Ardekani, B.A. (1) 269–281
Mugantseva, E., see Gureviciene, I. (1) 147–157
Muller, S., O. Preische, P. Heymann, U. Elbing and C. Laske, Diagnostic Value of a Tablet-Based Drawing Task for Discrimination of Patients in the Early Course of Alzheimer’s Disease from Healthy Individuals (4) 1463–1469
Mummery, C.J., see Golden, H.L. (3) 933–949
Munoz, D.G., see Kim, J. (1) 381–389
Munoz, D.G., see Sennik, S. (4) 1519–1528
Muñoz-Neira, C., see Slachevsky, A. (4) 1595–1603
Muraca, M.G., see Cupidi, C. (3) 1249–1259
Murad, H., see Cohen-Manheim, I. (3) 1207–1221
Murray, A.M., see Vemuri, P. (3) 1069–1082
Must, A., see Nemeth,V.L. (3) 865–880
Myllykangas, L., see Kuuluvainen, L. (3) 1167–1174
Myung, W., C. Lee, J.H. Park, S.-y. Woo, S. Kim, S. Kim, J.W. Chung, H.S. Kang, S.-W. Lim, J. Choi, D.L. Na, S.Y. Kim, J.-H. Lee, S.-H. Han, S.H. Choi, S.Y. Kim, B.J. Carroll and D.K. Kim, Occupational Attainment as Risk Factor for Progression from Mild Cognitive Impairment to Alzheimer’s Disease: A CREDOS Study (1) 283–292
Na, D.L., see Myung, W. (1) 283–292
Nagels, G., see Goossens, J. (1) 53–58
Nakamura, H., see Noguchi-Shinohara, M. (3) 905–913
Nardini, M., see Papazacharias, A. (3) 973–979
Naudé, P.J.W., see Dekens, D.W. (2) 763–776
Nemati, Z., see Coskun, P. (2) 737–748
Nemeth,V.L., A. Must, S. Horvath, A. Király, Z.T. Kincses and L. Vécsei, Gender-Specific Degeneration of Dementia-Related Subcortical Structures Throughout the Lifespan (3) 865–880
Nencioni, A., see Monacelli, F. (4) 1295–1306
Neumaier, B., see Dronse, J. (2) 465–471
Neumann, T., see Kara, K. (1) 359–369
Newhouse, S., see Voyle, N. (4) 1417–1427
Ng, L.L., see Peh, C.X. (2) 823–833
Ngah, W.Z.W. W.Z.W., see Ibrahim, N.F. (2) 597–612
Ngandu, T., see Pekkala, T. (3) 1055–1067
Nicholas, J.M., see Golden, H.L. (3) 933–949
Nicholson, L.K., see Fisher, C.L. (1) 391–410
Nielson, K.A., see Reiter, K. (4) 1363–1377
Nilson, A.N., K.C. English, J.E. Gerson, T.B. Whittle, C.N. Crain, J. Xue, U. Sengupta, D.L. Castillo-Carranza, W. Zhang, P. Gupta and R. Kayed, Tau Oligomers Associate with Inflammation in the Brain and Retina of Tauopathy Mice and in Neurodegenerative Diseases (3) 1083–1099
Ninomiya, T., see Hamasaki, H. (2) 613–624
Noguchi-Shinohara, M., J. Komatsu, M. Samuraki, I. Matsunari, T. Ikeda, K. Sakai, T. Hamaguchi, K. Ono, H. Nakamura and M. Yamada, Cerebral Amyloid Angiopathy-Related Microbleeds and Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease (3) 905–913
Nos, C., see Grau-Rivera, O. (1) 431–443
Nunomura, A., X. Zhu and G. Perry, Modulation of Parkinson’s Disease Associated Protein Rescues Alzheimer’s Disease Degeneration (1) 73–75
Ochi, M., see Igase, M. (4) 1481–1487
Ochoa, J.F., J.F. Alonso, J.E. Duque, C.A. Tobón, M.A. Mañanas, F. Lopera and A.M. Hernández, Successful Object Encoding Induces Increased Directed Connectivity in Presymptomatic Early-Onset Alzheimer’s Disease (3) 1195–1205
Odetti, P., see Monacelli, F. (4) 1295–1306
Oh, J.M., see Darst, B.F. (2) 473–484
Ohara, M., see Igase, M. (4) 1481–1487
Ohara, T., see Hamasaki, H. (2) 613–624
Ohyagi, Y., see Igase, M. (4) 1481–1487
Okada, Y., see Igase, M. (4) 1481–1487
Okamoto, N., M. Morikawa, N. Amano, M. Yanagi, S. Takasawa and N. Kurumatani, Effects of Tooth Loss and the Apolipoprotein E ɛ4 Allele on Mild Memory Impairment in the Fujiwara-kyo Study of Japan: A Nested Case-Control Study (2) 575–583
Okamoto, T., see Hamasaki, H. (2) 613–624
Okonkwo, O.C., see Darst, B.F. (2) 473–484
Olcese, J., see Beesley, S. (3) 1155–1166
Oleksik, A.M., see Jansen, W.J. (2) 679–689
Olsson, T., see Cebers, G. (3) 1039–1053
Ong, H., see McClure, R. (2) 797–811
Ono, K., see Ibrahim, N.F. (2) 597–612
Ono, K., see Noguchi-Shinohara, M. (3) 905–913
Onur, O.A., see Dronse, J. (2) 465–471
Ormel, P.R., see Philippens, I.H. (1) 101–113
Oulès, B., see Prete, D.D. (4) 1549–1570
Ou-Yang, M.-H., see Anderson, M. (3) 1109–1121
Paananen, J., see Laiterä, T. (3) 995–1003
Padilla, K., see Mendiola-Precoma, J. (3) 1273–1283
Pae, C.-U., see Han, J.W. (2) 787–796
Paetau, A., see Kuuluvainen, L. (3) 1167–1174
Pandya, S., A. Kuceyeski and A. Raj for the Alzheimer’s Disease Neuroimaging Initiative, The Brain’s Structural Connectome Mediates the Relationship between Regional Neuroimaging Biomarkers in Alzheimer’s Disease (4) 1639–1657
Panza, F., see Papazacharias, A. (3) 973–979
Papazacharias, A., M. Lozupone, M.R. Barulli, R. Capozzo, B.P. Imbimbo, F. Veneziani, R. De Blasi, M. Nardini, D. Seripa, F. Panza and G. Logroscino, Bipolar Disorder and Frontotemporal Dementia: An Intriguing Association (3) 973–979
Pařízková, M., R. Andel, O. Lerch, H. Marková, I. Gažová, M. Vyhnálek, J. Hort and J. Laczó, Homocysteine and Real-Space Navigation Performance among Non-Demented Older Adults (3) 951–964
Paraskevas, G.P., D. Kasselimis, E. Kourtidou, V. Constantinides, A. Bougea, C. Potagas, I. Evdokimidis and E. Kapaki, Cerebrospinal Fluid Biomarkers as a Diagnostic Tool of the Underlying Pathology of Primary Progressive Aphasia (4) 1453–1461
Parchi, P., see Rumeileh, S.A. (4) 1471–1480
Park, J.H., see Jacob, L. (1) 259–267
Park, J.H., see Myung, W. (1) 283–292
Park, K.-w., see An, H. (2) 727–735
Park, S.Y., see Kim, H.-R. (1) 137–146
Park, Y.H., see Kim, H.-R. (1) 137–146
Parnetti, L., see Lewczuk, P. (1) 159–170
Parnetti, L., see Lewczuk, P. (2) 813–822
Pasanen, P., see Kuuluvainen, L. (3) 1167–1174
Pásaro, E., see Valdiglesias, V. (4) 1509–1517
Pascual-Leone, A., see Fried, P.J. (1) 89–100
Pasquier, F., see Wawrziczny, E. (2) 703–716
Patel, H., see Voyle, N. (4) 1417–1427
Paterlini, A., see H. Bea Kuiperij, (2) 585–595
Paterlini-Bréchot, P., see Prete, D.D. (4) 1549–1570
Paterson, R.W., see Golden, H.L. (3) 933–949
Pautassi, R., see Abrevaya, S. (4) 1429–1435
Pavia, J., see Buongiorno, M. (3) 1261–1272
Peh, C.X., E. Abdin, J.A. Vaingankar, S. Verma, B.Y. Chua, V. Sagayadevan, E. Seow, Y. Zhang, S. Shahwan, L.L. Ng, M. Prince, S.A. Chong and M. Subramaniam, Validation of a Latent Construct for Dementia in a Population-Wide Dataset from Singapore (2) 823–833
Pekkala, T., A. Hall, J. Lötjönen, J. Mattila, H. Soininen, T. Ngandu, T. Laatikainen, M. Kivipelto and A. Solomon, Development of a Late-Life Dementia Prediction Index with Supervised Machine Learning in the Population-Based CAIDE Study (3) 1055–1067
Pelagallo, E., see Cerami, C. (1) 183–197
Peles, P.R.H., see Miranda, L.F.J.R. (2) 539–549
Perani, D., see Cerami, C. (1) 183–197
Pereira, F.H., see Miranda, L.F.J.R. (2) 539–549
Perestelo-Pérez, L., see Rivero-Santana, A. (2) 625–644
Perez, R.G., see Moss, D.E. (3) 1285–1294
Perret-Liaudet, A., see Lewczuk, P. (1) 159–170
Perry, G. see Nunomura, A. (1) 73–75
Perry, G., see Rueli, R.H.L.H. (2) 749–762
Petersen, R.C., see Savica, R. (2) 559–567
Petersen, S., S. Houston, H. Qin, C. Tague and J. Studley, The Utilization of Robotic Pets in Dementia Care (2) 569–574
Pham, W., see McClure, R. (2) 797–811
Philippens, I.H., P.R. Ormel, G. Baarends, M. Johansson, E.J. Remarque and M. Doverskog, Acceleration of Amyloidosis by Inflammation in the Amyloid-Beta Marmoset Monkey Model of Alzheimer’s Disease (1) 101–113
Phillips, J.I., see Lusardi, T.A. (3) 1223–1233
Pianetti, G.A., see Miranda, L.F.J.R. (2) 539–549
Pijnenburg, Y.A.L., see H. Bea Kuiperij, (2) 585–595
Pijnenburg, Y.A.L., see Hafkemeijer, A. (2) 521–537
Pike, I., see Russell, C.L. (1) 303–313
Pinchas-Mizrachi, R., see Cohen-Manheim, I. (3) 1207–1221
Pineda, D., see Abrevaya, S. (4) 1429–1435
Pinton, P., see Prete, D.D. (4) 1549–1570
Pipingas, A., see Kennedy, G. (1) 1–18
Pirisi, M., see Sainaghi, P.P. (1) 59–65
Pistilli, A., see Crispoltoni, L. (3) 1005–1017
Popp, J., see Lewczuk, P. (1) 159–170
Porsteinsson, A.P., see Lin, F., (2) 669–678
Potagas, C., see Paraskevas, G.P. (4) 1453–1461
Pöyhönen, M., see Kuuluvainen, L. (3) 1167–1174
Preische, O., see Muller, S. (4) 1463–1469
Prete, D.D., J.M. Suski, B. Oulès, D. Debayle, A.S. Gay, S. Lacas-Gervais, R. Bussiere, C. Bauer, P. Pinton, P. Paterlini-Bréchot, M.R. Wieckowski, F. Checler and M. Chami, Localization and Processing of the Amyloid- Protein Precursor in Mitochondria-Associated Membranes (4) 1549–1570
Prince, M., see Peh, C.X. (2) 823–833
Puccio, G., see Cupidi, C. (3) 1249–1259
Qin, H., see Petersen, S. (2) 569–574
Quarmley, M., P.J. Moberg, D. Mechanic-Hamilton, S. Kabadi, S.E. Arnold, D.A. Wolk and D.R. Roalf, Odor Identification Screening Improves Diagnostic Classification in Incipient Alzheimer’s Disease (4) 1497–1507
Quinn, J.F., see Lusardi, T.A. (3) 1223–1233
Raaphorst, J., see H. Bea Kuiperij, (2) 585–595
Racine, A.M., see Darst, B.F. (2) 473–484
Ræder, J., see Idland, A.-V. (1) 371–379
Raha, A.A., J.W. Henderson, S.R.W. Stott, R. Vuono, S. Foscarin, R.P. Friedland, S.H. Zaman and R. Raha-Chowdhury, Neuroprotective Effect of TREM-2 in Aging and Alzheimer’s Disease Model (1) 199–217
Raha-Chowdhury, R., see Raha, A.A. (1) 199–217
Raj, A., see Pandya, S. (4) 1639–1657
Ralph, J., see Fong, J.C. (1) 249–258
Ramakers, I.H.G.B., see Jansen, W.J. (2) 679–689
Ramírez, I., see Buongiorno, M. (3) 1261–1272
Rankin, K.P., see Fong, J.C. (1) 249–258
Rao, S.M., see Reiter, K. (4) 1363–1377
Raunig, D., see Arnerić, S.P. (1) 19–35
Rauramaa, T., see Laiterä, T. (3) 995–1003
Reid, R.I., see Vemuri, P. (3) 1069–1082
Reiter, K., K.A. Nielson, S. Durgerian, J.L. Woodard, J.C. Smith, M. Seidenberg, D.A. Kelly and S.M. Rao, Five-Year Longitudinal Brain Volume Change in Healthy Elders at Genetic Risk for Alzheimer’s Disease (4) 1363–1377
Remarque, E.J., see Philippens, I.H. (1) 101–113
Remes, A.M., see Laiterä, T. (3) 995–1003
Ren, P., see Lin, F., (2) 669–678
Rende, M., see Crispoltoni, L. (3) 1005–1017
Resnick, R.J., see Fisher, C.L. (1) 391–410
Reyes, P., see Slachevsky, A. (4) 1595–1603
Ribeiro, V.V., see Miranda, L.F.J.R. (2) 539–549
Ricci, C., see Zimetti, F., (1) 315–320
Richardson, J.C., see Waldron, A.-M. (4) 1537–1548
Richter, S., see Wucherer, D. (2) 691–701
Rikkert, M.O., see Freeze, W.M. (1) 333–342
Rikkert, M.O., see Jansen, W.J. (2) 679–689
Rio, S., see Leger, D. (1) 321–331
Ríos, J., see Buongiorno, M. (3) 1261–1272
Riva, G., see Serino, S. (3) 881–892
Rivero-Santana, A., D. Ferreira, L. Perestelo-Pérez, E. Westman, L.-O. Wahlund, A. Sarría and P. Serrano-Aguilar, Cerebrospinal Fluid Biomarkers for the Differential Diagnosis between Alzheimer’s Disease and Frontotemporal Lobar Degeneration: Systematic Review, HSROC Analysis, and Confounding Factors (2) 625–644
Rivers-Auty, J., see Martins, I.V.A. (3) 915–932
Rizzi, R., see Rumeileh, S.A. (4) 1471–1480
Roalf, D.R., see Quarmley, M. (4) 1497–1507
Roberts, R.O., see Savica, R. (2) 559–567
Robillard, J.M. and T.L. Feng, Health Advice in a Digital World: Quality and Content of Online Information about the Prevention of Alzheimer’s Disease (1) 219–229
Robinson, J.K., see Anderson, M. (3) 1109–1121
Rochina, M.J., see de la Rubia Ortí, J.E. (3) 899–903
Rockwood, K., see Cummings, J. (3) 1131–1139
Rodríguez Cruz, Y., M. Strehaiano, T. Rodríguez Obaya, J.C.G. Rodríguez and T. Maurice, An Intranasal Formulation of Erythropoietin (Neuro-EPO) Prevents Memory Deficits and Amyloid Toxicity in the APPSwe Transgenic Mouse Model of Alzheimer’s Disease (1) 231–248
Rodríguez Obaya, T., see Rodríguez Cruz, Y. (1) 231–248
Rodríguez, J.C.G., see Rodríguez Cruz, Y. (1) 231–248
Rodríguez-Cruz, A., see Mendiola-Precoma, J. (3) 1273–1283
Rojas, J.C., see Fong, J.C. (1) 249–258
Romanello, M., see Cupidi, C. (3) 1249–1259
Rombouts, S.A.R.B., see Hafkemeijer, A. (2) 521–537
Romero, K., see Arnerić, S.P. (1) 19–35
Ronda, N., see Zimetti, F., (1) 315–320
Rosen, L., see Cebers, G. (3) 1039–1053
Rueli, R.H.L.H., D.J. Torres, A.S.T. Dewing, A.C. Kiyohara, S.M. Barayuga, M.T. Bellinger, J.H. Uyehara-Lock, L.R. White, P.I. Moreira, M.J. Berry, G. Perry and F.P. Bellinger, Selenoprotein S Reduces Endoplasmic Reticulum Stress-Induced Phosphorylation of Tau: Potential Role in Selenate Mitigation of Tau Pathology (2) 749–762
Rumeileh, S.A., F. Lattanzio, M.S. Maserati, R. Rizzi, S. Capellari and P. Parchi, Diagnostic Accuracy of a Combined Analysis of Cerebrospinal Fluid t-PrP, t-tau, p-tau, and Ab42 in the Differential Diagnosis of Creutzfeldt-Jakob Disease from Alzheimer’s Disease with Emphasis on Atypical Disease Variants (4) 1471–1480
Rummukainen, J., see Kuuluvainen, L. (3) 1167–1174
Rundel, C., see Lin, K.A. (3) 1123–1130
Ruscica, M., see Zimetti, F., (1) 315–320
Russell, C.L., V. Mitra, K. Hansson, K. Blennow, J. Gobom, H. Zetterberg, M. Hiltunen, M. Ward and I. Pike, Comprehensive Quantitative Profiling of Tau and Phosphorylated Tau Peptides in Cerebrospinal Fluid by Mass Spectrometry Provides New Biomarker Candidates (1) 303–313
Russell, M., see Cebers, G. (3) 1039–1053
Ryu, H.J., M. Kim, Y. Moon, Y. Choi, J.-Y. Han, J.E. Galvin and S.-H. Han, Validation of the Korean Version of the Lewy Body Composite Risk Score (K-LBCRS) (4) 1395–1401
Ryu, S.-H., see Han, J.W. (2) 787–796
Ryu, S.-H., see Jacob, L. (1) 259–267
Sagayadevan, V., see Peh, C.X. (2) 823–833
Sager, M.A., see Darst, B.F. (2) 473–484
Sainaghi, P.P., M. Bellan, F. Lombino, F. Alciato, M. Carecchio, D. Galimberti, C. Fenoglio, E. Scarpini, R. Cantello, M. Pirisi and C. Comi, Growth Arrest Specific 6 Concentration is Increased in the Cerebrospinal Fluid of Patients with Alzheimer’s Disease (1) 59–65
Saito, T., see Iwahara, N. (3) 1235–1247
Sakai, K., see Noguchi-Shinohara, M. (3) 905–913
Salazar, F., see Buongiorno, M. (3) 1261–1272
Samtani, M.N., see Arnerić, S.P. (1) 19–35
Samuraki, M., see Noguchi-Shinohara, M. (3) 905–913
Sancesario, G.M., S. Toniolo, D. Chiasserini, S.G. Di Santo, J. Zegeer, G. Bernardi for SIBioC-Study Group of Clinical Biochemistry of Biological Fluids other than Blood, Massimo Musiccof for SINdem-ITALPLANED, Carlo Caltagirone, Lucilla Parnetti and Sergio Bernardini, The Clinical Use of Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease Diagnosis: The Italian Selfie (4) 1659–1666
Sanchez-Etayo, G., see Buongiorno, M. (3) 1261–1272
Sánchez-Valle, R., see Grau-Rivera, O. (1) 431–443
Santangelo, R., see Cerami, C. (1) 183–197
Santos, T., see Carmona-Iragui, M. (4) 1489–1496
Santos, T.R., see Miranda, L.F.J.R. (2) 539–549
Sarajärvi, T., see Laiterä, T. (3) 995–1003
Sarno, T.A., L.L.Talib, H.P.G. Joaquim, J.M. de França Bram, W.F.Gattaz and O.V. Forlenza, Protein Expression of BACE1 is Downregulated by Donepezil in Alzheimer’s Disease Platelets (4) 1445–1451
Sarría, A., see Rivero-Santana, A. (2) 625–644
Sato, S., see Kazui, H. (4) 1403–1416
Saugstad, J.A., see Lusardi, T.A. (3) 1223–1233
Saunders, C., see Beesley, S. (3) 1155–1166
Savage, M., see Arnerić, S.P. (1) 19–35
Savica, R., A.M.V. Wennberg, C. Hagen, K. Edwards, R.O. Roberts, J.H. Hollman, D.S. Knopman, B.F. Boeve, M.M. Machulda, R.C. Petersen and M.M. Mielke, Comparison of Gait Parameters for Predicting Cognitive Decline: The Mayo Clinic Study of Aging (2) 559–567
Saxena, S., see Fried, P.J. (1) 89–100
Scarpini, E., see Sainaghi, P.P. (1) 59–65
Schelhaas, H.J., see H. Bea Kuiperij, (2) 585–595
Scheltens, P., see Cummings, J. (3) 1131–1139
Scheltens, P., see Hafkemeijer, A. (2) 521–537
Scheltens, P., see Jansen, W.J. (2) 679–689
Schena, F., see Crispoltoni, L. (3) 1005–1017
Schependom, J.V., see Goossens, J. (1) 53–58
Schiano, I., see de la Monte, S.M. (2) 849–864
Schilberg, L., see Fried, P.J. (1) 89–100
Schmidt, M., see Waldron, A.-M. (4) 1537–1548
Scholey, A.B., see Kennedy, G. (1) 1–18
Schott, J.M., see Golden, H.L. (3) 933–949
Schriner, S.E., see Coskun, P. (2) 737–748
Schroeder, F.C., see Fisher, C.L. (1) 391–410
Schweizer, T.A., see Kim, J. (1) 381–389
Schweizer, T.A., see Sennik, S. (4) 1519–1528
Sedeño, L., see Abrevaya, S. (4) 1429–1435
Seidenberg, M., see Reiter, K. (4) 1363–1377
Sengupta, U., see Nilson, A.N. (3) 1083–1099
Senjem, M.L., see Krishnan, K. (3) 1019–1029
Sennik, S., T.A. Schweizer, C.E. Fischer and D.G. Munoz, Risk Factors and Pathological Substrates Associated with Agitation/Aggression in Alzheimer’s Disease: A Preliminary Study using NACC Data (4) 1519–1528
Seow, E., see Peh, C.X. (2) 823–833
Serino, S. and G. Riva, The Proactive Self in Space: How Egocentric and Allocentric Spatial Impairments Contribute to Anosognosia in Alzheimer’s Disease (3) 881–892
Seripa, D., see Papazacharias, A. (3) 973–979
Serra, L., M. Mancini, M. Cercignani, C. Di Domenico, B. Spanò, G. Giulietti, G. Koch, C. Marra and M. Bozzali, Network-Based Substrate of Cognitive Reserve in Alzheimer’s Disease (1) 421–430
Serrano-Aguilar, P., see Rivero-Santana, A. (2) 625–644
Shah, R.C., see Cummings, J. (3) 1131–1139
Shahwan, S., see Peh, C.X. (2) 823–833
Shaw, L., see Arnerić, S.P. (1) 19–35
Shen, Y., Y. Xia, S. Meng, N.K.H. Lim, W. Wang and F. Huang, SH2B1 is Involved in the Accumulation of Amyloid-β42 in Alzheimer’s Disease (2) 835–847
Sherman, C., see Chau, S.A. (4) 1339–1349
Shi, M., see Banks, W.A. (1) 411–419
Shim, S.-M., H.-S. Cheon, C. Jo, Y.H. Koh, J. Song and J.-P. Jeon, Elevated Epstein-Barr Virus Antibody Level is Associated with Cognitive Decline in the Korean Elderly (1) 293–301
Shimohama, S., see Iwahara, N. (3) 1235–1247
Shimohama, S., see Kitamura, Y. (1) 67–72
Shimosegawa, E., see Kazui, H. (4) 1403–1416
Sieben, A., see Goossens, J. (1) 53–58
Siitonen, M., see Kuuluvainen, L. (3) 1167–1174
Silveira, J.N., see Miranda, L.F.J.R. (2) 539–549
Simon, E.S., see Cohen-Manheim, I. (3) 1207–1221
Singh, V., see Hilt, S. (4) 1667–1681
Sinnreich, R., see Cohen-Manheim, I. (3) 1207–1221
Slachevsky, A., L. Guzmán-Martínez, C. Delgado, P. Reyes, G.A. Farías, C. Muñoz-Neira, E. Bravo, M. Farías, P. Flores, C. Garrido, J.T. Becker, O.L. López and R.B. Maccioni, Tau Platelets Correlate with Regional Brain Atrophy in Patients with Alzheimer’s Disease (4) 1595–1603
Slattery, C.F., see Golden, H.L. (3) 933–949
Slinin, Y., see Vemuri, P. (3) 1069–1082
Smania, N., see Crispoltoni, L. (3) 1005–1017
Smid, M., see Jansen, W.J. (2) 679–689
Smirne, N., see Cupidi, C. (3) 1249–1259
Smith, J.C., see Reiter, K. (4) 1363–1377
Smith, M.A., see Dengler-Crish, C.M. (4) 1605–1619
Sohn, Y.H., see Kim, Y. (2) 485–495
Soininen, H., see Laiterä, T. (3) 995–1003
Soininen, H., see Pekkala, T. (3) 1055–1067
Soler, M., see Buongiorno, M. (3) 1261–1272
Solomon, A., see Pekkala, T. (3) 1055–1067
Song, J., see Shim, S.-M. (1) 293–301
Song, M., see Xie, B. (2) 509–520
Spallazzi, M., see Zimetti, F., (1) 315–320
Spanò, B., see Serra, L. (1) 421–430
Spitzer, P., see Lewczuk, P. (1) 159–170
Spychalla, A.J., see Krishnan, K. (3) 1019–1029
Stabile, A.M., see Crispoltoni, L. (3) 1005–1017
Staelens, S., see Waldron, A.-M. (4) 1537–1548
Stemmelin, J., see Leger, D. (1) 321–331
Stephenson, D., see Arnerić, S.P. (1) 19–35
Støen, R., see Idland, A.-V. (1) 371–379
Stott, S.R.W., see Raha, A.A. (1) 199–217
Strand, E.A., see Krishnan, K. (3) 1019–1029
Strauss, M., see Leger, D. (1) 321–331
Strehaiano, M., see Rodríguez Cruz, Y. (1) 231–248
Strohmaier, U., see Teipel, S.J. (4) 1379–1394
Stroobants, S., see Waldron, A.-M. (4) 1537–1548
Struyfs, H., see Goossens, J. (1) 53–58
Studley J., see Petersen, S. (2) 569–574
Subramaniam, M., see Peh, C.X. (2) 823–833
Suehiro, T., see Kazui, H. (4) 1403–1416
Sun, L., K. Chen, X. Li and S. Xiao, Rapidly Progressive Frontotemporal Dementia Associated with MAPT Mutation G389R (2) 777–785
Sun, Y., see Wang, Y. (4) 1683–1692
Suski, J.M., see Prete, D.D. (4) 1549–1570
Suzuki, H., see Iwahara, N. (3) 1235–1247
Suzuki, S., see Iwahara, N. (3) 1235–1247
Suzuki, S.O., see Hamasaki, H. (2) 613–624
Suzuki, Y., see Kazui, H. (4) 1403–1416
Szablewski, L., Glucose Transporters in Brain: In Health and in Alzheimer’s Disease (4) 1307–1320
Tabara, Y., see Igase, M. (4) 1481–1487
Tabernero, A., see Domínguez-Prieto, M. (1) 171–182
Tague, C., see Petersen, S. (2) 569–574
Takahashi, R., see Kazui, H. (4) 1403–1416
Takasawa, S., see Okamoto, N. (2) 575–583
Takata, K., see Kitamura, Y. (1) 67–72
Talib, L.L., see Sarno, T.A. (4) 1445–1451
Tan, H., see Wang, Y. (4) 1683–1692
Tanaka, T., see Kazui, H. (4) 1403–1416
Tang, T., see Hilt, S. (4) 1667–1681
Tanila, H., see Gureviciene, I. (1) 147–157
Teipel, S., see Wucherer, D. (2) 691–701
Teipel, S.J., F. Keller, J.R. Thyrian, U. Strohmaier, A. Altiner, W. Hoffmann and I. Kilimann, Hippocampus and Basal Forebrain Volumetry for Dementia and Mild Cognitive Impairment Diagnosis: Could It Be Useful in Primary Care? (4) 1379–1394
Terjestam, Y., see Håkansson, K. (2) 645–657
Teunissen, C.E., see H. Bea Kuiperij, (2) 585–595
Teunissen, C.E., see Lewczuk, P. (1) 159–170
Thomas, J., see Coskun, P. (2) 737–748
Thostenson, K.B., see Vemuri, P. (3) 1069–1082
Thyrian, J.R., see Teipel, S.J. (4) 1379–1394
Thyrian, J.R., see Wucherer, D. (2) 691–701
Tienari, P.J., see Kuuluvainen, L. (3) 1167–1174
Tito, P.A.L., see Miranda, L.F.J.R. (2) 539–549
Tobón, C.A., see Ochoa, J.F. (3) 1195–1205
Tong, M., see de la Monte, S.M. (2) 849–864
Tong, Z., W. Wang, W. Luo, J. Lv, H. Li, H. Luo, J. Jia and R. He, Urine Formaldehyde Predicts Cognitive Impairment in Post-Stroke Dementia and Alzheimer’s Disease (3) 1031–1038
Toniolo, S., see Sancesario, G.M. (4) 1659–1666
Tooyama, I., see Ibrahim, N.F. (2) 597–612
Tooyama, I., see Kitamura, Y. (1) 67–72
Torchia, G., see Cupidi, C. (3) 1249–1259
Torres, D.J., see Rueli, R.H.L.H. (2) 749–762
Tremblay, C., see Dal-Pan, A. (1) 115–135
Trujillo, N., see Abrevaya, S. (4) 1429–1435
Tsuji, M., see Ibrahim, N.F. (2) 597–612
Turco, M., see Cagnin, A. (4) 1529–1536
Turnbull, M.T. and E.J. Coulson, Cholinergic Basal Forebrain Lesion Decreases Neurotrophin Signaling without Affecting Tau Hyperphosphorylation in Genetically Susceptible Mice (3) 1141–1154
Ulstein, I. and T. Bøhmer, Normal Vitamin Levels and Nutritional Indices in Alzheimer’s Disease Patients with Mild Cognitive Impairment or Dementia with Normal Body Mass Indexes (2) 717–725
Umek, R.M., see Arnerić, S.P. (1) 19–35
Uyehara-Lock, J.H., see Rueli, R.H.L.H. (2) 749–762
Vaingankar, J.A., see Peh, C.X. (2) 823–833
Valdiglesias, V., A. Maseda, L. Lorenzo-López, E. Pásaro, J.C. Millán-Calenti and B. Laffon, Is Salivary Chromogranin A a Valid Psychological Stress Biomarker During Sensory Stimulation in People with Advanced Dementia? (4) 1509–1517
Valeria De Marco, E., see Cuccaro, D. (1) 37–52
Valldeoriola, F., see Buongiorno, M. (3) 1261–1272
Van Broeckhoven, C., see Goossens, J. (1) 53–58
van Buchem, M.A., see Freeze, W.M. (1) 333–342
Van Dam, D., see Dekens, D.W. (2) 763–776
van den Berg-Huysmans, A.A., see Hafkemeijer, A. (2) 521–537
Van den Bossche, T., see Goossens, J. (1) 53–58
van der Flier, W.M., see Freeze, W.M. (1) 333–342
van der Flier, W.M., see Hafkemeijer, A. (2) 521–537
van der Grond, J., see Hafkemeijer, A. (2) 521–537
van der Lugt, A., see Wolters, F.J. (3) 893–897
van der Zee, J., see Goossens, J. (1) 53–58
van Domburg, P., see Jansen, W.J. (2) 679–689
van Eimeren, T., see Dronse, J. (2) 465–471
Van Mossevelde, S., see Goossens, J. (1) 53–58
Van Nostrand, W.E., see Anderson, M. (3) 1109–1121
van Swieten, J.C., see Hafkemeijer, A. (2) 521–537
Vanderstichele, H., see Arnerić, S.P. (1) 19–35
Varma, V.R. and A. Watts, Daily Physical Activity Patterns During the Early Stage of Alzheimer’s Disease (2) 659–667
Vasso, F., see Cupidi, C. (3) 1249–1259
Vécsei, L., see Nemeth,V.L. (3) 865–880
Vega, L., see Domínguez-Prieto, M. (1) 171–182
Velasco, A., see Domínguez-Prieto, M. (1) 171–182
Vemuri, P., D.S. Knopman, C.R. Jack Jr, E.S. Lundt, S.D. Weigand, S.M. Zuk, K.B. Thostenson, R.I. Reid, K. Kantarci, Y. Slinin, K. Lakshminarayan, C.S. Davey and A.M. Murray, Association of Kidney Function Biomarkers with Brain MRI Findings: The BRINK Study (3) 1069–1082
Veneziani, F., see Papazacharias, A. (3) 973–979
Venturelli, M., see Crispoltoni, L. (3) 1005–1017
Verbeek, M.M., see Freeze, W.M. (1) 333–342
Verbeek, M.M., see H. Bea Kuiperij, (2) 585–595
Verhaeghe, J., see Waldron, A.-M. (4) 1537–1548
Verhey, F., see Jansen, W.J. (2) 679–689
Verhey, F.R., see Freeze, W.M. (1) 333–342
Verma, S., see Peh, C.X. (2) 823–833
Vermeiren, Y., see Dekens, D.W. (2) 763–776
Vermette, A., see Bergeron, D. (4) 1335–1337
Vernooij, M.W., see Wolters, F.J. (3) 893–897
Vernooij-Dassen, M., see Mariani, E. (4) 1621–1638
Versleijen, A.A.M., see H. Bea Kuiperij, (2) 585–595
Verwey, N.A., see H. Bea Kuiperij, (2) 585–595
Viard, A., see Duclos, H. (2) 459–463
Videla, L., see Carmona-Iragui, M. (4) 1489–1496
Videla, S., see Carmona-Iragui, M. (4) 1489–1496
Villegas, A., see Abrevaya, S. (4) 1429–1435
Visser, P.J., see Jansen, W.J. (2) 679–689
Visser, P.J., see Voyle, N. (4) 1417–1427
von Reutern, B., see Dronse, J. (2) 465–471
Vos, S.J., see Freeze, W.M. (1) 333–342
Voshaar, R.C.O., see Dekens, D.W. (2) 763–776
Voss,J.C., see Hilt, S. (4) 1667–1681
Voyle, N., H. Patel, A. Folarin, S. Newhouse, C. Johnston, P.J. Visser, R.J.B. Dobson and S.J. Kiddle the EDAR and DESCRIPA study groups and the Alzheimer’s Disease Neuroimaging Initiative, Genetic Risk as a Marker of Amyloid-b and Tau Burden in Cerebrospinal Fluid (4) 1417–1427
Vrenken, H., see Hafkemeijer, A. (2) 521–537
Vuono, R., see Raha, A.A. (1) 199–217
Vyhnálek, M., see Pařízková, M. (3) 951–964
Wahlund, L.-O., see Andreotti, J. (3) 981–993
Wahlund, L.-O., see Rivero-Santana, A. (2) 625–644
Waldron, A.-M., L. wyffels, J. Verhaeghe, J.C. Richardson, M. Schmidt, S. Stroobants, X. Langlois and S. Staelens, Longitudinal Characterization of [18F]-FDG and [18F]-AV45 Uptake in the Double Transgenic TASTPM Mouse Model (4) 1537–1548
Wallace, D.C., see Coskun, P. (2) 737–748
Walton, J.H., see Hilt, S. (4) 1667–1681
Wang, J.-F., see Wang, Y. (4) 1683–1692
Wang, M.J., see Kim, H.-R. (1) 137–146
Wang, W., see Shen, Y. (2) 835–847
Wang, W., see Tong, Z. (3) 1031–1038
Wang, X., see Xie, B. (2) 509–520
Wang, Y., see Wang, Y. (4) 1683–1692
Wang, Y., Z. Zhou, H. Tan, S. Zhu, Y. Wang, Y. Sun, X.-M. Li and J.-F. Wang, Nitrosylation of Vesicular Transporters in Brain of Amyloid Precursor Protein/ Presenilin 1 Double Transgenic Mice (4) 1683–1692
Ward, M., see Russell, C.L. (1) 303–313
Warren, J.D., see Golden, H.L. (3) 933–949
Watne, L.O., see Idland, A.-V. (1) 371–379
Watts, A., see Varma, V.R. (2) 659–667
Wawrziczny, E., G. Berna, F. Ducharme, M.-J. Kergoat, F. Pasquier and P. Antoine, Modeling the Distress of Spousal Caregivers of People with Dementia (2) 703–716
Weigand, S.D., see Vemuri, P. (3) 1069–1082
Weimar, C., see Kara, K. (1) 359–369
Wennberg, A.M.V., see Savica, R. (2) 559–567
Westman, E., see Rivero-Santana, A. (2) 625–644
White, L.R., see Rueli, R.H.L.H. (2) 749–762
Whittle, T.B., see Nilson, A.N. (3) 1083–1099
Whitwell, J.L., see Krishnan, K. (3) 1019–1029
Wieckowski, M.R., see Prete, D.D. (4) 1549–1570
Wiedrick, J.T., see Lusardi, T.A. (3) 1223–1233
Wijker, W., see Cummings, J. (3) 1131–1139
Wilkinson, D., see Cummings, J. (3) 1131–1139
Willis, B., see Arnerić, S.P. (1) 19–35
Wilson, G.N., see Dengler-Crish, C.M. (4) 1605–1619
Winblad, B., see Håkansson, K. (2) 645–657
Winkler, A., see Kara, K. (1) 359–369
Wolfs, C., see Jansen, W.J. (2) 679–689
Wolk, D.A., see Quarmley, M. (4) 1497–1507
Wolters, F.J., D. Bos, M.W. Vernooij, O.H. Franco, The Heart-Brain Connection collaborative research group, A. Hofman, P.J. Koudstaal, A. van der Lugt and M.A. Ikram, Aortic Valve Calcification and the Risk of dementia: A Population-Based Study (3) 893–897
Wong, B., see Fried, P.J. (1) 89–100
Woo, S.-y., see Myung, W. (1) 283–292
Woodard, J.L., see Reiter, K. (4) 1363–1377
Woods, R.T., see Yates, J.A., (3) 1183–1193
Wu, T., see Zhang, Y.-P. (2) 497–507
Wucherer, D., T. Eichler, J. Hertel, I. Kilimann, S. Richter, B. Michalowsky, J.R. Thyrian, S. Teipel and W. Hoffmann, Potentially Inappropriate Medication in Community-Dwelling Primary Care Patients who were Screened Positive for Dementia (2) 691–701
Wulff, H., see Hilt, S. (4) 1667–1681
wyffels, L., see Waldron, A.-M. (4) 1537–1548
Wyller, T.B., see Idland, A.-V. (1) 371–379
Xia, Y., see Shen, Y. (2) 835–847
Xiao, S., see Sun, L. (2) 777–785
Xie, B., Z. Liu, L. Jiang, W. Liu, M. Song, Q. Zhang, R. Zhang, D. Cui, X. Wang and S. Xu, Increased Serum miR-206 Level Predicts Conversion from Amnestic Mild Cognitive Impairment to Alzheimer’s Disease: A 5-Year Follow-up Study (2) 509–520
Xing, T., see Zhuang, X. (3) 1101–1108
Xu, F., see Anderson, M. (3) 1109–1121
Xu, S., see Xie, B. (2) 509–520
Xue, J., see Nilson, A.N. (3) 1083–1099
Yamada, M., see Noguchi-Shinohara, M. (3) 905–913
Yamamoto, Y., see Kazui, H. (4) 1403–1416
Yanagi, M., see Okamoto, N. (2) 575–583
Yanagisawa, D., see Ibrahim, N.F. (2) 597–612
Yanagisawa, D., see Kitamura, Y. (1) 67–72
Yang, D.-W., see An, H. (2) 727–735
Yang, X., see Zhuang, X. (3) 1101–1108
Yates, J.A., L. Clare and R.T. Woods in collaboration with The Cognitive Function and Ageing Study: Wales, What is the Relationship between Health, Mood, and Mild Cognitive Impairment? (3) 1183–1193
Ye, B.S., see Kim, Y. (2) 485–495
Ye, N., see Cebers, G. (3) 1039–1053
Yokokawa, K., see Iwahara, N. (3) 1235–1247
Yoon, J.C., see Jacob, L. (1) 259–267
Yoshiyama, K., see Kazui, H. (4) 1403–1416
Youn, J.C., see Han, J.W. (2) 787–796
Yule, S., see Arnerić, S.P. (1) 19–35
Zaman, S.H., see Raha, A.A. (1) 199–217
Zampieri, S., see Cupidi, C. (3) 1249–1259
Zanotti, I., see Zimetti, F., (1) 315–320
Zegeer, J., see Sancesario, G.M. (4) 1659–1666
Zetterberg, H., see Darst, B.F. (2) 473–484
Zetterberg, H., see Idland, A.-V. (1) 371–379
Zetterberg, H., see Lewczuk, P. (1) 159–170
Zetterberg, H., see Russell, C.L. (1) 303–313
Zhang, J., see Banks, W.A. (1) 411–419
Zhang, Q., see Xie, B. (2) 509–520
Zhang, R., see Xie, B. (2) 509–520
Zhang, S., see Chang, P. (1) 77–87
Zhang, W., see Nilson, A.N. (3) 1083–1099
Zhang, Y., see Peh, C.X. (2) 823–833
Zhang, Y.-P., R. Miao, Q. Li, T. Wu and F. Ma, Effects of DHA Supplementation on Hippocampal Volume and CognitiveFunction in Older Adults with Mild Cognitive Impairment: A 12-Month Randomized, Double-Blind, Placebo-Controlled Trial (2) 497–507
Zhang, Z., see Chang, P. (1) 77–87
Zhou, Z., see Wang, Y. (4) 1683–1692
Zhu, M., see McClure, R. (2) 797–811
Zhu, S., see Wang, Y. (4) 1683–1692
Zhu, X., see Nunomura, A. (1) 73–75
Zhuang, X., see Zhuang, X. (3) 1101–1108
Zhuang, X., Y. Chen, X. Zhuang, T. Xing, T. Chen, G. Jiang and X. Yang, Impaired Center-Surround Suppression in Patients with Alzheimer’s Disease (3) 1101–1108
Zijlstra, W., see Fleiner, T. (4) 1583–1594
Zimetti, F., P. Caffarra, N. Ronda, E. Favari, M.P. Adorni, I. Zanotti, F. Bernini, F. Barocco, M. Spallazzi, D. Galimberti, C. Ricci, M. Ruscica, A. Corsini and N. Ferri, Increased PCSK9 Cerebrospinal Fluid Concentrations in Alzheimer’s Disease (1) 315–320
Zuk, S.M., see Vemuri, P. (3) 1069–1082